The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney diseases. ASN gratefully acknowledges the following companies for their contributions in 2022.

### DIAMOND LEVEL

<table>
<thead>
<tr>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSL Vifor</td>
</tr>
<tr>
<td>Fresenius Medical Care</td>
</tr>
<tr>
<td>Otsuka Group of Companies</td>
</tr>
</tbody>
</table>

### PLATINUM LEVEL

<table>
<thead>
<tr>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
</tr>
<tr>
<td>calliditas Therapeutics</td>
</tr>
<tr>
<td>ChemoCentryx</td>
</tr>
<tr>
<td>Chinook Therapeutics</td>
</tr>
</tbody>
</table>

### GOLD LEVEL

<table>
<thead>
<tr>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akebia Therapeutics, Inc.</td>
</tr>
<tr>
<td>Mallinckrodt Pharmaceuticals</td>
</tr>
<tr>
<td>Nipro Medical Corporation</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals</td>
</tr>
</tbody>
</table>

### SILVER LEVEL

<table>
<thead>
<tr>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexion Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Novartis</td>
</tr>
<tr>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Renalytix</td>
</tr>
<tr>
<td>Horizon Therapeutics</td>
</tr>
<tr>
<td>Verici Dx</td>
</tr>
<tr>
<td>Natera</td>
</tr>
</tbody>
</table>

### BRONZE LEVEL

<table>
<thead>
<tr>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANI Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>DaVita</td>
</tr>
<tr>
<td>Ardelyx</td>
</tr>
<tr>
<td>Eurofins Transplant Diagnostics</td>
</tr>
<tr>
<td>Aurinia Pharma U.S.</td>
</tr>
<tr>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>Bayer</td>
</tr>
<tr>
<td>OPKO Renal</td>
</tr>
<tr>
<td>CareDx</td>
</tr>
<tr>
<td>Sanofi</td>
</tr>
<tr>
<td>CVS Kidney Care</td>
</tr>
</tbody>
</table>

As of September 20, 2022
TABLE OF CONTENTS

Kidney Week Mobile App .................................................. 2
Welcome ........................................................................ 3
Schedule-at-a-Glance ....................................................... 4
Health and Safety ............................................................ 6
Accreditation, CE Credits, MOC Points ...................... 8
Certificates of Attendance for International Participants 9
Day-at-a-Glance: Wednesday, November 2 (Early Programs) 11
Day-at-a-Glance: Thursday, November 3 ....................... 14
Day-at-a-Glance: Friday, November 4 ............................ 30
Day-at-a-Glance: Saturday, November 5 ....................... 46
Scientific Exposition: November 3–5 ......................... 59
Exhibitor Spotlights: November 3–5 ......................... 60
Day-at-a-Glance: Sunday, November 6 ....................... 64
LGBTQ+ Owned and Friendly Local Businesses and Organizations 68

Attention US Health Professionals

To ensure full compliance with the Open Payments (Physician Payments Sunshine Act), a provision of the Patient Protection and Affordable Care Act (PL 111-148) that requires applicable manufacturers and applicable group purchasing organizations to report financial payments made to US physicians and select other US healthcare professionals, including as part of supported ASN activities. ASN reserves the right to provide information to such entities about US physicians, US physician assistants, and US advanced practice nurses (and their spouses) who participate in selected ASN activities. Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open Payments. The program increases public awareness of financial relationships between drug and device manufacturers and certain health care providers. ASN makes reasonable attempts to collect and maintain the following information about its US physician members: 1) name and business address, 2) specialty, 3) National Provider Identification (NPI) number, and 4) state(s) professional license number and name of state(s) issuing license.

In the event that ASN receives payment from an applicable sponsor and the sponsor requests the reportable information from ASN, ASN will provide the information under the condition that the sponsor agrees to use the data only for reporting purposes covered under the Act and no other purpose.

US physicians have certain rights under this Act, and more information about these rights can be found at the resources listed below.

To learn more, please go to the US Government’s Center for Medicare & Medicaid Services (CMS) website, www.cms.gov/openpayments. Additional information can be found at the American Medical Association’s website.
Download the Meeting Mobile App

Navigate the meeting like a pro with the meeting mobile app.

- Stay organized with current program, exhibitor, and meeting information.
- Receive important real-time communications from ASN.
- Build a personalized schedule, and bookmark exhibitors.
- Stay in-the-know, and join the social media dialogue.

And much, much more!

The Kidney Week Mobile App is supported by
Welcome to ASN Kidney Week 2022

ASN proudly welcomes you to Kidney Week, the world’s premier nephrology meeting. At Kidney Week, the world’s leading experts share new approaches to health care, research, education, and policy. Participants have opportunities to network with fellow specialists, advance their careers, learn best practices for treating and improving the lives of people with kidney diseases, and collaborate with colleagues from around the world.

Leading the fight against kidney diseases for over 55 years, ASN represents health professionals whose intellectual rigor, integrity, and ingenuity advance kidney research, treatment, and policy and improve the lives of millions of patients.

ASN Council
Susan E. Quaggin, MD, FASN, President
Anupam Agarwal, MD, FASN, Past President
Michelle A. Josephson, MD, FASN, President-Elect
Deidra C. Crews, MD, MS, FASN, Secretary
Keisha L. Gibson, MD, MPH, FASN, Treasurer
Linda F. Fried, MD, MPH, FASN, Councilor
Crystal A. Gadegbeku, MD, FASN, Councilor
Patrick H. Nachman, MD, FASN, Councilor
Prabir Roy-Chaudhury, MD, PhD, FASN, Councilor

Kidney Week Education Committee
Kirk N. Campbell, MD, FASN, Co-Chair
Catherine Godson, PhD, Co-Chair
George L. Bakris, MD, FASN
Moumita Barua, MD
Tammy M. Brady, MD, PhD
Hui Cai, MD, FASN
Kerri L. Cavanaugh, MD, MPH
Mark E. Cooper, MBBS, PhD, FASN
Stanley D. Crittenden, MD, FASN
Alessia Fornoni, MD, PhD, FASN
Donald Fraser, MBChB, PhD
Lorenzo G. Gallon, MD
Anna Greka, MD, PhD
Karen A. Griffin, MD, FASN
Orlando M. Gutierrez, MD
Mark Haas, MD, PhD
Jeffrey B. Hodgin, MD, PhD
Pinelopi P. Kapitsinou, MD
Beom Seok Kim, MD, PhD
Lisa A. Koester Wiedemann, ANP, CNN-NP
James P. Lash, MD, FASN
Rachel Lennon, MBBS, PhD
Tingting Li, MD, MSc, FASN
Valeria R. Mas, PhD
Precious McCowan, MS
Dianne B. McKay, MD
Helen McNeill, PhD
Patrick T. Murray, MD, FASN
Samir M. Parikh, MD, FASN
Mark A. Perazella, MD, FASN
Catherine Quinlan, MD
Wendy L. St. Peter, PharmD, FASN
Jason R. Stubbs, MD
Volker Vallon, MD, FASN

Kidney Week 2022 educational programming is supported in part from an educational grant from CVS Kidney Care.
## Schedule-at-a-Glance

<table>
<thead>
<tr>
<th>Day</th>
<th>AM</th>
<th>8:00</th>
<th>8:30</th>
<th>9:00</th>
<th>9:30</th>
<th>10:00</th>
<th>10:30</th>
<th>11:00</th>
<th>11:30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday, November 3</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCSS, CPS, TS, SS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Educational Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scientific Exposition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Friday, November 4</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCSS, CPS, TS, SS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Educational Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scientific Exposition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Saturday, November 5</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCSS, CPS, TS, SS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Educational Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Abstract Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Sessions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scientific Exposition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sunday, November 6</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary Session and ASN Business Meeting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCSS, CPS, TS, SS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### LEGEND

- **BCSS** - Basic/Clinical Science Sessions
- **CPS** - Clinical Practice Sessions
- **SS** - Special Sessions
- **TS** - Translational Sessions
TS - Translational Sessions
SS - Special Sessions

Schedule-at-a-Glance

Thursday, November 3 AM
8:00  8:30  9:00  9:30  10:00  10:30  11:00  11:30
PM
12:00  12:30  1:00  1:30  2:00  2:30  3:00  3:30  4:00  4:30  5:00  5:30  6:00  6:30  7:00

Plenary Session
BCSS, CPS, TS, SS
Educational Symposia
Oral Abstract Sessions
Poster Sessions
Ask the Author
Scientific Exposition
Exhibitor Spotlights

Friday, November 4 AM
8:00  8:30  9:00  9:30  10:00  10:30  11:00  11:30
PM
12:00  12:30  1:00  1:30  2:00  2:30  3:00  3:30  4:00  4:30  5:00  5:30  6:00  6:30  7:00

Plenary Session
BCSS, CPS, TS, SS
Educational Symposia
Oral Abstract Sessions
Poster Sessions
Ask the Author
Scientific Exposition
Exhibitor Spotlights

Saturday, November 5 AM
8:00  8:30  9:00  9:30  10:00  10:30  11:00  11:30
PM
12:00  12:30  1:00  1:30  2:00  2:30  3:00  3:30  4:00  4:30  5:00  5:30  6:00  6:30  7:00

Plenary Session
BCSS, CPS, TS, SS
Educational Symposia
Oral Abstract Sessions
Poster Sessions
Ask the Author
Scientific Exposition
Exhibitor Spotlights

Sunday, November 6 AM
8:00  8:30  9:00  9:30  10:00  10:30  11:00  11:30
PM
12:00  12:30  1:00  1:30  2:00  2:30  3:00  3:30  4:00  4:30  5:00  5:30  6:00  6:30  7:00

Plenary Session and
ASN Business Meeting
BCSS, CPS, TS, SS

Welcome Reception
Health and Safety

**Proof of Vaccination**
ALL in-person attendees, staff, vendors, and all other participants are required to provide proof that they are fully vaccinated or will be fully vaccinated for COVID-19 by October 31, 2022, prior to Kidney Week. Because Kidney Week is an international meeting that will take place in the United States, ASN can only recognize vaccines that are fully approved or authorized for use during a public health emergency by the US Food and Drug Administration’s Emergency Use Authorization or by the World Health Organization’s Emergency Use Listing.

**Mask Requirement**
ASN requires masks for all in-person participants, unless they are actively eating or drinking, at all ASN official events, including but not limited to those taking place at the Orange County Convention Center, Hyatt Regency Orlando, other ASN official hotels, and on shuttles.

**Physical Distancing**
All in-person participants should expect physical distancing in high-traffic areas, meeting rooms, exhibit floor, and event space in accordance with local and venue regulations. Kidney Week will adhere to capacity standards in accordance with local and state authorities to control the density of the exhibit floor and meeting rooms.

Attendee/audience seating may be modified to allow for compliance with reduced capacity guidelines, and room sets may be modified to accommodate increased spacing. All educational sessions will be recorded and will be available on the Kidney Week virtual platform for both in-person and virtual participants.

**Health Monitoring**
All in-person participants should monitor their health before and during Kidney Week. If you are experiencing any symptoms, please do not attend any Kidney Week sessions or events.

**Assumption of Risk and Waiver of Claims**
Participants choosing to attend in-person agreed to the terms of the Assumption of Risk and Waiver of Claims (“Waiver”) during the registration process. By agreeing to this Waiver, participants acknowledge that they have made the decision to attend Kidney Week in-person with the full understanding of the inherent risks of such decision and acknowledge and agree to these risks.

**International Attendance**
Please refer to the US Department of State’s COVID-19 Travel Information for air travelers to the US. This information continues to be updated and is subject to change.
**Food and Beverage**  
Water bottles are encouraged, and water coolers are placed in strategic locations throughout the Orange County Convention Center.

Food and beverage events are optional to all participants, and participants may remove masks while actively eating or drinking.

**Cleaning and Disinfecting**  
Meeting rooms and foyer spaces will be thoroughly cleaned overnight and will be cleaned during the day between sessions.

Restrooms will be regularly and thoroughly cleaned during event hours and include the following touch-free items: soap dispensers, sink faucets, toilet fixtures, paper towel and toilet paper dispensers.

Hand-sanitizer stations will be provided near building entrances, meeting rooms, and lobbies. Touch-free dispensers will be used wherever possible, and a schedule will be established for re-filling the stations.

**Hotels**  
All hotels within the Kidney Week hotel block have implemented the following measures:
- Heightened cleaning protocols for high-traffic areas such as the front desk, fitness centers, and pools, as well as other high-touch surfaces throughout the hotel, using hospital-grade disinfectant approved by the US Environmental Protection Agency (EPA) to combat the spread of COVID-19.
- Reduced contact at check-in and digital check-in provided.
- Furniture arrangements designed to encourage appropriate social distancing.
- Housekeeping “on-demand” options that allows guests to request delivery of additional toiletries, towels, linens, or coffee without having a housekeeper enter the room.

**Shuttle Buses**  
Kidney Week’s shuttle bus partner, SEAT Planners, has developed “Clean SEAT” guidelines for the travel and event industry. SEAT Planners partners with local operators that ensure drivers are healthy and symptom-free before leaving the operator’s yard. Drivers will clean high-touch areas throughout the day using recommended personal protective equipment (PPE) and disinfectants.

Attendees utilizing shuttle buses will be required to practice posted personal safety guidelines for travelers.
Accreditation, CE Credits, MOC Points
(Annual Meeting, November 3–6)

Learning Objectives
At the conclusion of this activity, participants will have increased knowledge in the field of nephrology and will be able to:
1. Identify recent discoveries in basic, translational, and clinical research in nephrology.
2. Construct new research questions based on updated scientific and clinical advances in nephrology-related disciplines.
3. Translate recent advances in the areas of general nephrology, dialysis, transplantation, and hypertension into new standards and approaches to clinical care of patients with kidney diseases and related disorders.

Target Audience
- Physicians
- PhDs and Other Researchers
- Medical and Other Trainees—including medical students, residents, graduate students, post-docs, and fellows
- Nurses and Nurse Practitioners
- Pharmacists
- Physician Assistants
- Other Health Care Professionals

Accreditation Statement
In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Medical Education Credits
AMA CREDIT DESIGNATION STATEMENT – PHYSICIANS
The American Society of Nephrology designates this blended learning activity for a maximum of 75.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC CREDIT DESIGNATION STATEMENT – NURSES
This CE activity is approved for 75.0 ANCC contact hours.

ACPE CREDIT DESIGNATION STATEMENT – PHARMACISTS
This activity has been approved for 75.0 contact hours.

AAPA/NCCPA CREDIT DESIGNATION STATEMENT – PHYSICIAN ASSISTANTS
Physician Assistants may receive a maximum of 75.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

ASN values each participant’s review and comments on the quality of ASN’s educational activities. Please complete the evaluation at www.asn-online.org/elearning by December 31, 2022. Instructions are available on the ASN website and at ASN Services in the West Lobby D of the convention center.

Note: For Early Program credits, please refer to the program materials.
Maintenance of Certification (MOC) Points

The Kidney Week Annual Meeting offers MOC Points for American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) Diplomates with the completion of a reflective statement and commitment-to-change questions in this activity’s evaluation. Instructions are available on the ASN website and ASN eLearning Center.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 75 MOC points in the ABIM Maintenance of Certification (MOC) program; and
- 75 MOC points in the ABP Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.

Statement from ABIM
This course has been developed as an original and independent educational offering based on the public ABIM examination blueprint and is not approved or endorsed by ABIM. In accordance with ABIM policy, no ABIM Board members have been involved in the development of this course. ASN cannot guarantee that attending this course will result in passing the ABIM examination.

Disclosure Statement
It is the policy of the American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN’s sponsored continuing education (CE) activities are expected to provide full disclosure for both themselves and their spouse/partner, and to indicate to the activity audience any financial or other relationship held by themselves or their spouse/partner 1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial service(s) discussed in an educational presentation; and 2) with any commercial supporter(s) of the activity. All responses should reflect activities within the previous 24 months. Furthermore, ASN requests all faculty to disclose at the time of their lecture any planned discussion of investigational and/or off-label use of pharmaceutical products or devices within their presentation. Participants should note that the use of products outside US Food and Drug Administration (FDA)–approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CE, but rather to ensure that ASN CE activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty members were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

ASN requires all individuals in a position to control content for Kidney Week to complete disclosure forms. Responses are listed on the ASN website, in the meeting platform, and during sessions.

Certificates of Attendance for International Participants

Early Program participants can pick up printed Certificates of Attendance (not CE certificates for US participants) on Wednesday, November 2 at the programs. Annual Meeting participants can access online Certificates of Attendance (not CE certificates for US participants) from November 3, 2022, through February 3, 2023, at https://show.jspargo.com/asn22/certificateofAttendance/. Certificates are only available if you have picked up your meeting materials or printed your meeting badge onsite. If you have questions, please visit ASN Services in the West Lobby D of the convention center.
UNITED TO MAKE A DIFFERENCE.

Join the kidney health professionals who are embracing four priorities to move us closer to our goal of a world without kidney diseases.

ASN
American Society of Nephrology
DAY-AT-A-GLANCE
Wednesday, November 2

Early Programs

Each Early Program requires separate registration from the Annual Meeting.

The following in-person Early Programs do not have onsite registration:

Advances in Research Conference: Regenerative Medicine and Bioartificial Kidneys ............... W230
7:00 a.m. Onsite Check-In and Continental Breakfast
8:00 a.m. Onsite Sessions
5:00 p.m. Adjourn

Fundamentals of Renal Pathology ......................................................................................................................... W222
7:00 a.m. Onsite Check-In and Continental Breakfast
8:00 a.m. Onsite Sessions
5:35 p.m. Adjourn

Point-of-Care Ultrasound in Nephrology ........................................................................................................... W221
In-kind support is provided by EchoNous, Inc., FUJIFILM Sonosite, Inc., GE Healthcare,
Philips Healthcare North America.
7:00 a.m. Onsite Check-In and Continental Breakfast
8:00 a.m. Onsite Sessions
4:30 p.m. Adjourn

The following fully virtual Early Programs do not have onsite activities:

Critical Care Nephrology: 2022 Update
Glomerular Diseases: 2022 Update
Support is provided by an educational grant from Travere Therapeutics, Inc.

Maintenance Dialysis
Renal Physiology: Structure and Function in Kidney Health and Disease

Scan the QR code from the ScanHunt tab of the Kidney Week 2022 app.
Download the mobile app to play!

Check out the ScanHunt game in the meeting app for a chance to win a Kidney Week 2023 registration.

Scan various QR codes in the convention center and the Hyatt Regency Orlando to earn points. Participants with 100 or more points will be entered to win one of 3 complimentary registrations.

Search Kidney Week in your app store or scan the QR code here.
Community Lounge Events

Make the most of your time at ASN Kidney Week 2022 with quick, informal sessions about the value of community discussions, networking, and collaboration. Also enjoy the relaxation area with complimentary massages (first-come, first-served).

### Thursday
**Nov. 3**

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview of Communities</td>
<td>10:00 – 11:00 a.m.</td>
</tr>
<tr>
<td>Profile components, account preferences, navigation tips</td>
<td></td>
</tr>
<tr>
<td>Becoming a Community Leader</td>
<td>11:00 a.m. – 12:00 p.m.</td>
</tr>
<tr>
<td>Engagement strategies, moderation, replies, follow-through</td>
<td></td>
</tr>
<tr>
<td>Mentor Match Program</td>
<td>12:00 – 1:00 p.m.</td>
</tr>
<tr>
<td>Enrollment basics, search criteria, building relationships</td>
<td></td>
</tr>
<tr>
<td>Communities Office Hours</td>
<td>1:00 – 1:30 p.m.</td>
</tr>
<tr>
<td>Meet &amp; greets, questions &amp; answers</td>
<td></td>
</tr>
</tbody>
</table>

### Friday
**Nov. 4**

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Art of Discussion</td>
<td>10:00 – 11:00 a.m.</td>
</tr>
<tr>
<td>Tips &amp; strategies, best practices, seed questions, quality content</td>
<td></td>
</tr>
<tr>
<td>General &amp; Clinical Nephrology Poster Tour</td>
<td>11:00 a.m. – 12:00 p.m.</td>
</tr>
<tr>
<td>Led by Edgar Lerma, MD, FASN and Roger Rodby, MD, FASN</td>
<td></td>
</tr>
<tr>
<td>Hot Topics</td>
<td>12:00 – 1:00 p.m.</td>
</tr>
<tr>
<td>COVID-19, transplantation, dialysis safety</td>
<td></td>
</tr>
<tr>
<td>Networking and Collaboration</td>
<td>1:00 – 1:30 p.m.</td>
</tr>
<tr>
<td>Leveraging connections, sharing stories, team projects</td>
<td></td>
</tr>
</tbody>
</table>

### Saturday
**Nov. 5**

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Communities Library</td>
<td>10:00 – 11:00 a.m.</td>
</tr>
<tr>
<td>Keyword searching, studies &amp; reports, credible research</td>
<td></td>
</tr>
<tr>
<td>Early Career Focus</td>
<td>11:00 a.m. – 12:00 p.m.</td>
</tr>
<tr>
<td>STARS, TREKS, in-training exam, the nephrology match</td>
<td></td>
</tr>
<tr>
<td>Themed Communities</td>
<td>12:00 – 1:00 p.m.</td>
</tr>
<tr>
<td>Onco-Nephrology, Kidney Transplantation, Women’s Health &amp; Research</td>
<td></td>
</tr>
<tr>
<td>Open Discussion</td>
<td>1:00 – 1:30 p.m.</td>
</tr>
<tr>
<td>New ideas, future directions, lingering questions</td>
<td></td>
</tr>
</tbody>
</table>

Join an intimate group of your peers as you listen and partake in conversations.
Community Lounge Events

Make the most of your time at ASN Kidney Week 2022 with quick, informal sessions about the value of community discussions, networking, and collaboration. Also enjoy the relaxation area with complimentary massages (first-come, first-served).

Thursday
Overview of Communities                                   10:00 – 11:00 a.m.
Profile components, account preferences, navigation tips
Becoming a Community Leader
11:00 a.m. – 12:00 p.m.
Engagement strategies, moderation, replies, follow-through
Mentor Match Program
12:00 – 1:00 p.m.
Enrollment basics, search criteria, building relationships
Communities Office Hours
1:00 – 1:30 p.m.
Meet & greets, questions & answers

Friday
The Art of Discussion                                            10:00 – 11:00 a.m.
Tips & strategies, best practices, seed questions, quality content
General & Clinical Nephrology Poster Tour
11:00 a.m. – 12:00 p.m.
Led by Edgar Lerma, MD, FASN and Roger Rodby, MD, FASN
Hot Topics
12:00 – 1:00 p.m.
COVID-19, transplantation, dialysis safety
Networking and Collaboration
1:00 – 1:30 p.m.
Leveraging connections, sharing stories, team projects

Saturday
Communities Library                                            10:00 – 11:00 a.m.
Keyword searching, studies & reports, credible research
Early Career Focus                                        11:00 a.m. – 12:00 p.m.
STARS, TREKS, in-training exam, the nephrology match
Themed Communities                                            12:00 – 1:00 p.m.
Onco-Nephrology, Kidney Transplantation, Women's Health & Research
Open Discussion                                                     1:00 – 1:30 p.m.
New ideas, future directions, lingering questions

The gifted fellows and early-career investigators funded by KidneyCure share your commitment to making a difference for the millions of patients impacted by kidney diseases. These trailblazers, working across the kidney research spectrum, are finding new paths to conquering diseases, such as Tanecia Mitchell, PhD, whose novel method of measuring dietary oxalate aims to better understand, prevent, and treat kidney stone formation.

Your support is crucial to keeping brilliant investigators like Tanecia in the field and on track to making important discoveries.

Tanecia Mitchell, PhD
2021-2022 Transition to Independence Grant Recipient
University of Alabama at Birmingham

Make a Difference

Use your phone’s camera to scan the QR code.

Or visit: www.kidneycur.org/donate

“Receiving funding from KidneyCure not only supports the progression of my research but also confirms that my research is considered valuable to the field.”

Tanecia Mitchell, PhD
2021-2022 Transition to Independence Grant Recipient
University of Alabama at Birmingham

The gifted fellows and early-career investigators funded by KidneyCure share your commitment to making a difference for the millions of patients impacted by kidney diseases. These trailblazers, working across the kidney research spectrum, are finding new paths to conquering diseases, such as Tanecia Mitchell, PhD, whose novel method of measuring dietary oxalate aims to better understand, prevent, and treat kidney stone formation.

Your support is crucial to keeping brilliant investigators like Tanecia in the field and on track to making important discoveries.
DAY-AT-A-GLANCE
Thursday, November 3

8:00 a.m. – 9:30 a.m.
Joint ASN-National Academy of Medicine Opening Plenary: ASN President’s Address,
   Expert Panel “Preventing the Next Pandemic” .................................................................W415 Valencia

9:30 a.m. – 2:30 p.m.
Morning Break (9:30 a.m. – 10:00 a.m.)............................................................................West Exhibit Hall D
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)....................................................West Exhibit Hall D
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.)................................................West Exhibit Hall D

10:30 a.m. – 12:30 p.m.
Basic/Clinical Science Sessions
  Big Roles for Thin Limbs........................................................................................................W230
  Podocyte Development, Disease, and Stem Cell Research..................................................W240

Clinical Practice Sessions
  Health Care Equity for All: Improving the Experience of Patients with Kidney Diseases.....WF1 Tangerine
  Nephrology Consult Service in the Hospital: No Rest for the Weary ....................................W415 Valencia
  Novel Anticancer Therapies and Hypertension: The Role of the Nephrologist.......................W311
  Personalizing Prescriptions in Hemodialysis: A Path to Safer Care for All.........................WF2 Tangerine
  The Patient Journey with Diabetic Kidney Disease,
    Including the Garabed Eknoyan Endowed Lectureship.......................................................W224
  Tired of Debating the Limitations of eGFR? Do Your Patients a Favor and Measure GFR! ......W304

Translational Sessions
  Deep Dive into the Pathophysiology of Kidney Stone Formation........................................W414
  Organ Preservation into the 2020s: The Era of Dynamic Intervention................................WF3 Tangerine
  Prospects for Gene Therapy in Glomerular Disease,
    Including the Michelle P. Winn Endowed Lectureship.......................................................W320 Chapin

Other Events
  Fellows-in-Training Bowl: Elimination Rounds.................................................................West Exhibit Hall D
  Reimagining Nephrology Fellowship Training:
    Recommendations from the 2022 ASN Task Force on the Future of Nephrology............W315

12:45 p.m. – 1:45 p.m.
Educational Symposia (Hyatt Regency Orlando) – Doors open at 12:30 p.m.
  Hope in ADPKD: Innovation in Therapeutics..........................................................Windermere Ballroom X
  IgA Nephropathy: The Role of the Renal Endothelin System and
    Other Therapeutic Implications.................................................................Regency Ballroom R
  Management of Hyperphosphatemia in Patients with ESKD,
    Especially During the COVID-19 Pandemic............................................................Regency Ballroom S
  Updates on Therapeutic Options for Anemia in Kidney Diseases....................................Regency Ballroom T

2:00 p.m. – 4:00 p.m.
Basic/Clinical Science Sessions
  Alternative Animal Models of Kidney Development and Repair.......................................WF1 Tangerine
  Applications of Artificial Intelligence to Medical Kidney Biopsy Interpretation....................W315
  Cell-to-Cell Chats in the Diabetic Kidney............................................................................W224
  Controversies in Phosphorus Homeostasis and Management in CKD.................................W414
  Metabolism and Kidney Diseases......................................................................................W230
  Skeletal Muscle: An Underappreciated Target Organ in CKD............................................W304
  Untangling Determinants of AKI Through an -Omics Approach,
    Including the Robert W. Schrier Endowed Lectureship................................................W308
2:00 p.m. – 4:00 p.m.

**Clinical Practice Sessions**

A Look in the Crystal Ball: COVID-19 and the Future of Outpatient Dialysis .......................... WF2 Tangerine

Case Studies in Glomerular Diseases 2022 ................................................................................. W320 Chapin

Current Approaches to the Management of Common Cardiorenal Syndromes ............................ W307

Novel Treatments for Resistant Hypertension in Advanced CKD ......................................................... W311

What Can Genomic Sequencing Offer People with CKD?............................................................... W240

**Translational Sessions**

Future Shock: Transformational Therapies for Kidney Failure ..................................................... WF3 Tangerine

New Directions and Strategies to Improve Hypertension and Pain Management in CKD ................... W415 Valencia

**Special Session**

Choose Your Own Adventure: Nephrology Career Paths ............................................................ W314

4:00 p.m. – 4:30 p.m.

**Afternoon Break** ........................................ West Lobby D, West Lobby E/F, W415 Valencia Foyer, W320 Foyer

4:30 p.m. – 6:00 p.m.

**Basic/Clinical Science Sessions**

Autosomal Dominant Tubulointerstitial Kidney Disease: New Diagnostics and Therapies .................. WF1 Tangerine

Impact of MicroRNAs and Circular RNAs on the Pathogenesis and Prognosis of Glomerular Diseases .................................................................................................................... W304

**Clinical Practice Sessions**

Implementing the Race-Free eGFR Equations in Clinical Practice: Where Are We Now? ..................... WF2 Tangerine

Why Allografts Fail: Clinical, Histopathological, and Molecular Approach to Chronic Allograft Injury, Including the Barbara T. Murphy Endowed Lectureship ........................ WF3 Tangerine

**Translational Session**

European Nephrology Highlights: Updates from the 2022 ERA Congress ........................................ W224

**Oral Abstract Sessions**

AKI Research: Prediction, Diagnosis, Recovery ............................................................................. W230

Dialysis: Patient-Centered Interventions and Outcomes .................................................................. W414

Hypertension and CVD: Epidemiology, Risk Factors, Prevention .................................................... W240

Pediatric Nephrology: From Bench to Bedside .............................................................................. W307

Technology-Based Approaches in Nephrology ............................................................................. W308

Transplantation: Basic Research ........................................................................................................ W314

**Topical Chats**

The IQ to Teach QI: Quality Teaching of Quality Improvement ..................................................... W221A

Promoting Diversity, Inclusivity, and Equity in Patient Care ......................................................... W221E

6:00 p.m. – 7:00 p.m.

**Welcome Reception** .................................................................................................................. West Exhibit Hall D

Download the meeting app or scan the QR code for more details and updates.
Joint ASN-National Academy of Medicine Opening Plenary:
ASN President’s Address, Expert Panel “Preventing the Next Pandemic” ............... W415 Valencia
ASN thanks the National Academy of Medicine and Dr. Victor Dzau for assistance with this session.

Thursday, November 3, 8:00 a.m. – 9:30 a.m.

8:00 a.m.   ASN President’s Address – Susan Quaggin
8:25 a.m.   “Preventing the Next Pandemic” Keynote – Peter Hotez
8:45 a.m.   “Preventing the Next Pandemic” Panel – Carlos del Rio (moderator),
            Timothy Evans, Peter Hotez, Jennifer Nuzzo, Reed Tuckson

Thursda...
Thursday, November 3, 10:30 a.m. – 12:30 p.m.

**Nephrology Consult Service in the Hospital: No Rest for the Weary**

Moderators: Lili Chan, Roger Rodby

10:30 a.m. **Panicked Call from the Hepatologist: Patient with Cirrhosis Has Anuric AKI and Needs CRRT** – Andrew Allegretti

11:00 a.m. **Urgent Consult from Your Oncology Colleague: Pediatric Patient with Lymphoma Has Tumor Lysis Syndrome and AKI** – Arwa Nada

11:30 a.m. **Stat Consult from the Cardiac Care Unit: Patient with Advanced Heart Failure Has Diuretic Resistance and AKI** – Jeffrey Turner

12:00 p.m. **Midnight Call from the Medical Intensive Care Unit: Patient with Complicated Sepsis on Extracorporeal Membrane Oxygenation Has Developed AKI** – J. Pedro Teixeira

**Novel Anticancer Therapies and Hypertension: The Role of the Nephrologist**

Moderators: Kenar Jhaveri, Sheron Latcha

10:30 a.m. **New-Onset Hypertension in Patients with Cancer Secondary to Cancer Therapies** – Gavin Oudit

11:00 a.m. **Mechanisms of Hypertension due to Vascular Endothelial Growth Factor (VEGF) Inhibitors** – Vesna Garovic

11:30 a.m. **Hypertension due to Non-VEGF-Pathway Anticancer Therapies** – Sandra Herrmann

12:00 p.m. **Distinct Approaches to Diagnosing, Monitoring, and Managing Hypertension in Patients with Cancer** – Agnes Kim

**Personalizing Prescriptions in Hemodialysis: A Path to Safer Care for All**

Moderators: Tara Chang, Joanna Hudson

10:30 a.m. **Symptoms in Hemodialysis: Advances in Assessment and Management to Reduce Harm** – Connie Rhee

11:00 a.m. **Personalizing Electrolytes in the Dialysis Prescription: Is That the Key?** – Talat Alp Ikizler

11:30 a.m. **Should We Evaluate and Address Weight at Every Dialysis Treatment?** – Jennifer Flythe

12:00 p.m. **Dialysis Modality Selection Counseling Should Not Be Limited to Initiation** – Keren Ladin

**The Patient Journey with Diabetic Kidney Disease,**

Including the Garabed Eknoyan, MD, Endowed Lectureship

Moderators: Ian de Boer, Susanne Nicholas

10:30 a.m. **Delay Does Not Mean Denial: A Patient’s Experience with DKD** – Patrick Gee

11:00 a.m. **Improving Awareness, Detection, and Interventions for Patients with DKD** – Amy Mottl

11:30 a.m. **Implementing Goal-Directed Medical Therapies for DKD:**

   The Garabed Eknoyan, MD, Endowed Lectureship – Katherine Tuttle

12:00 p.m. **Getting the Job Done with Value-Based Care for Patients with DKD** – Daniel Weiner

Program is subject to change.
Thursday, November 3, 10:30 a.m. – 12:30 p.m.

**Tired of Debating the Limitations of eGFR? Do Your Patients a Favor and Measure GFR!……W304**
Moderators: Harold Feldman, Delphine Tuot

- 10:30 a.m. **Individual-Level Inaccuracy of eGFR and Implications for Clinical Care** – Tariq Shafi
- 11:00 a.m. **GFR Measurement by Plasma Clearance Does Not Require Urine Collection** – Natalie Ebert
- 11:30 a.m. **GFR Measurement by Urinary Clearance Without an Intravenous Infusion** – Jesse Seegmiller
- 12:00 p.m. **Choosing the Best GFR Measurement Technique in Clinical Practice** – John Lieske

**Deep Dive into the Pathophysiology of Kidney Stone Formation.............................................W414**
Moderators: Kirsten Kusumi, Khashayar Sakhaee

- 10:30 a.m. **Evolving Understanding of Oxalate Metabolism in Humans** – Sonia Fargue
- 11:00 a.m. **Unraveling the Microstructural Elements of Kidney Stones and Randall Plaques** – James Williams
- 11:30 a.m. **Role of Innate Immunity Pathways in Regulating Stone Formation** – Tanecia Mitchell
- 12:00 p.m. **Contribution of Gut Microbes to Kidney Stone Formation** – Michelle Denburg

**Organ Preservation into the 2020s: The Era of Dynamic Intervention ......................WF3 Tangerine**
Moderators: Anil Chandraker, Mita Shah

- 10:30 a.m. **To Pump or Not to Pump: Machine Perfusion versus Cold Storage for Deceased Donor Kidney Transplantation** – Markus Selzner
- 11:00 a.m. **Inflammatory Landscape of the Perfused Kidney: New Interventions and Effects on Outcomes** – Annemarie Weissenbacher
- 11:30 a.m. **Mechanisms of Human Kidney Cold Storage and New Precision Therapies** – Gregory Tietjen
- 12:00 p.m. **Cryobiology to Stabilize the Donor Organ** – Erik Finger

**Prospects for Gene Therapy in Glomerular Disease, Including the Michelle P. Winn, MD, Endowed Lectureship .............................................W320 Chapin**
ASN gratefully acknowledges Duke University School of Medicine, the school’s Division of Nephrology, and several individuals for support of the Michelle P. Winn, MD, Endowed Lectureship.

Moderators: Friedhelm Hildebrandt, Kandai Nozu

- 10:30 a.m. **Experience from Clinical Trials of Immune Gene Therapies** – Waseem Qasim
- 11:00 a.m. **Targeting the Kidneys with Gene Therapy** – Matthew Wilson
- 11:30 a.m. **Adeno-Associated Virus (AAV) Genome Rescue of Nphs2 in Mice: The Michelle P. Winn, MD, Endowed Lectureship** – Moin Saleem
- 12:00 p.m. **Preclinical Gene Therapy Studies in Alport Syndrome Dogs** – Mary Nabity

**Fellows-in-Training Bowl: Elimination Rounds.....................................................West Exhibit Hall D**
Support is provided by Chinook Therapeutics, Inc.
Note: Continuing education credits are not being offered for this activity.

**Reimagining Nephrology Fellowship Training:**
Recommendations from the 2022 ASN Task Force on the Future of Nephrology....................W315
Note: Continuing education credits are not being offered for this activity.
Thursday, November 3, 12:45 p.m. – 1:45 p.m.

*Educational Symposia (Hyatt Regency Orlando)* – Doors open at 12:30 p.m.
Lunch is provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants.

**IgA Nephropathy: The Role of the Renal Endothelin System and Other Therapeutic Implications**
*Regency Ballroom R*

Support is provided by an educational grant from Travere Therapeutics, Inc.

12:45 p.m.  *Introduction* – Tingting Li (Moderator)
12:55 p.m.  *Proteinuria in IgA Nephropathy: Mechanisms and Clinical Implications* – Jonathan Barratt
1:15 p.m.  *Emerging Therapies in IgA Nephropathy: Targeting the Renal Endothelin System and Other Therapies* – Richard Lafayette
1:35 p.m.  Questions and Answers

**Management of Hyperphosphatemia in Patients with ESKD, Especially During the COVID-19 Pandemic**
*Regency Ballroom S*

Support is provided by an educational grant from Fresenius Medical Care.

12:45 p.m.  *Introduction: Phosphate Homeostasis and Hyperphosphatemia Management* – Elvira Gosmanova (Moderator)
12:55 p.m.  *Update on Hyperphosphatemia Management in Patients with ESKD, Especially During the COVID-19 Pandemic* – Michal Melamed
1:15 p.m.  *Organ Cross-Talk in Phosphate Homeostasis* – Sharon Moe
1:35 p.m.  Questions and Answers

**Updates on Therapeutic Options for Anemia in Kidney Diseases**
*Regency Ballroom T*

Support is provided by an educational grant from GlaxoSmithKline.

12:45 p.m.  *Introduction* – Fredric Finkelstein (Moderator)
12:55 p.m.  *Management of Anemia in Nondialysis CKD: Current Recommendations* – Bruce Robinson
1:15 p.m.  *Efficacy and Cardiovascular Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors* – Nupur Gupta
1:35 p.m.  Questions and Answers

Thursday, November 3, 2:00 p.m. – 4:00 p.m.

**Alternative Animal Models of Kidney Development and Repair**
*WF1 Tangerine*

Moderators: Iain Drummond, Leif Oxburgh

2:00 p.m.  *Rhesus Macaque as a Model for Human Lateral Branch Nephrogenesis* – Meredith Schuh
2:30 p.m.  *Spiny Mouse as a Model for Kidney Regeneration* – Daryl Okamura
3:00 p.m.  *Using Zebrafish to Model Kidney Development* – Rebecca Wingert
3:30 p.m.  *Using Frogs to Understand Cystic Kidney Disease* – Oliver Wessely

**Applications of Artificial Intelligence to Medical Kidney Biopsy Interpretation**
*W315*

Moderators: Laura Barisoni, Avi Rosenberg

2:00 p.m.  *Image Analysis in the Quantitation of Interstitial Fibrosis and Glomerulosclerosis* – Alton Farris
2:30 p.m.  *Computational Segmentation and Quantification in Diabetic Nephropathy* – Pinaki Sarder
3:00 p.m.  *Deep Learning Classification of Kidney Transplant Pathology* – Peter Boor
3:30 p.m.  *High-Throughput Quality Control, Annotation, and Labeling in Kidney Digital Pathology Repositories for Biomarker Discovery* – Andrew Janowczyk

Program is subject to change.
Thursday, November 3, 2:00 p.m. – 4:00 p.m.

Cell-to-Cell Chats in the Diabetic Kidney ................................................................. W224
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Michael Donnan, Agnes Fogo
2:00 p.m.  Visceral to Parietal Cell Chats – Sandeep Mallipattu
2:30 p.m.  Communicating Through Nanotubules – Federica Barutta
3:00 p.m.  Endothelial Cells to Podocytes and Back – Ilse Daehn
3:30 p.m.  Can Tubules Influence Glomerular Cell Function? – Roderick Tan

Controversies in Phosphorus Homeostasis and Management in CKD........................ W414
Moderators: Kenneth White, Myles Wolf
2:00 p.m. Soluble Klotho Has Direct Actions That Regulate Phosphorus Homeostasis – Li-Li Hsiao
2:30 p.m. Soluble Klotho Does Not Have Direct Actions That Regulate Phosphorus Homeostasis – Christian Faul
3:00 p.m. Reducing Dietary Phosphorus Intake Is Critical for Preventing CKD-MBD – Annabel Biruete
3:30 p.m. Reducing Dietary Phosphorus Intake Is Counterproductive in Preventing CKD-MBD – Kathleen Hill Gallant

Metabolism and Kidney Diseases ............................................................................. W230
Moderators: Jeanie Park, Sian Piret
2:00 p.m. Metabolic Decision in Development and Disease: Overview in Kidney Perspective – Scott Summers
2:30 p.m. Renal Metabolism and Hypertension – Mingyu Liang
3:00 p.m. Fructose Metabolism in Kidney Diseases – Miguel Lanaspa
3:30 p.m. Metabolic Reprogramming in PKD – Alessandra Boletta

Skeletal Muscle: An Underappreciated Target Organ in CKD................................. W304
Moderators: Clara Bohm, Hui Cai
2:00 p.m. Mitochondrial Health and Muscle Bioenergetics in CKD – Baback Roshanravan
2:30 p.m. Skeletal Muscle Regeneration and Fibrosis in CKD and Dialysis – Matthew Abramowitz
3:00 p.m. Muscle Wasting, Autophagy, and CKD – Xiaonan Wang
3:30 p.m. Insights into Muscle-Kidney Cross-Talk – Tobias Huber

Untangling Determinants of AKI Through an -Omics Approach, Including the Robert W. Schrier Endowed Lectureship .................................................. W308
ASN gratefully acknowledges Otsuka America Pharmaceutical, Novartis, Astellas Pharma US, and several individuals for support of the Robert W. Schrier, MD, Endowed Lectureship.
Moderators: Eugene Rhee, Tomokazu Souma
2:00 p.m. Spatial Transcriptomics in AKI – Eryn Dixon
2:30 p.m. Proteomics in AKI – Roman-Ulrich Mueller
3:00 p.m. Metabolomics in AKI – Samir Parikh
3:30 p.m. Integrating Analysis of Animal Models and Human Biopsies to Better Understand AKI: The Robert W. Schrier, MD, Endowed Lectureship – Lloyd Cantley
Thursday, November 3, 2:00 p.m. – 4:00 p.m.

A Look in the Crystal Ball: COVID-19 and the Future of Outpatient Dialysis............WF2 Tangerine
ASN thanks the ASN COVID-19 Response Team for assistance with this session.
Moderators: Brigitte Schiller, Jeffrey Silberzweig
2:00 p.m. Dialysis Facility Staffing in the Wake of COVID-19 – Jeffrey Hymes
2:30 p.m. Vaccine Requirements: Are Mandates Ethical? – Olivia Kates
3:00 p.m. ESRD Network Roles: Patient Resources and Regulatory – Kamyar Kalantar-Zadeh
3:30 p.m. Most Important Good and Bad Impacts of COVID in Dialysis – Dawn Edwards

Case Studies in Glomerular Diseases 2022 .................................................................W320 Chapin
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Leal Herlitz, Brad Rovin
2:00 p.m. Case 1 – Richard Lafayette
2:30 p.m. Case 2 – Keisha Gibson
3:00 p.m. Case 3 – Dawn Caster
3:30 p.m. Case 4 – Jonathan Barratt

Current Approaches to the Management of Common Cardiorenal Syndromes ............W307
Moderators: Josee Bouchard, Anitha Vijayan
2:00 p.m. Prevention and Management of AKI in Acute Heart Failure: The Importance of Decongestion – Janani Rangaswami
2:30 p.m. Prevention of Contrast-Associated AKI in Patients Undergoing Coronary Angiography – Neesh Pannu
3:00 p.m. Prevention and Management of AKI in Patients Undergoing Cardiac Surgery – Andrew Shaw
3:30 p.m. “Permissive AKI” Is the Price of Success When Using SGLT2 Inhibitors in Cardiorenal Syndromes – Adeera Levin

Novel Treatments for Resistant Hypertension in Advanced CKD .........................W311
Moderators: George Bakris, Karen Griffin
2:00 p.m. Nonsteroidal Mineralocorticoid Receptor Blocker (KBP-5074) for Hypertension in Stage 4 CKD – Pablo Pergola
2:30 p.m. Combined Endothelin A and B Antagonists in Patients with Stage 4 CKD – Ernesto Schiffin
3:00 p.m. Effects of Firibastat, a First-in-Class Centrally Acting Aminopeptidase Inhibitor on Resistant Hypertension – Michel Azizi
3:30 p.m. Kidney Denervation for Hypertension: Where We Are Now – Raymond Townsend

What Can Genomic Sequencing Offer People with CKD? .....................................W240
Moderators: Elhussein Elhassan, Mathieu Lemaire
2:00 p.m. Genomic Sequencing for Patients with Kidney Failure: What Is the Diagnostic Yield? – Jan Halbritter
2:30 p.m. Exploring the Impact of Genomic Sequencing for Patients with Established CKD – Ali Gharavi
3:00 p.m. Health Economic Argument for Early Genomic Sequencing for Patients with CKD – Paola Romagnani
3:30 p.m. Diagnostic Yield and Clinical Utility of Genomic Sequencing for Children with CKD – Asheeta Gupta
Thursday, November 3, 2:00 p.m. – 4:00 p.m.

Future Shock: Transformational Therapies for Kidney Failure .............................................WF3 Tangerine
Support is provided by an educational grant from eGenesis, Inc.
Moderators: Raymond Harris, Melissa West
2:00 p.m. Where Are We with Portable and Wearable Hemodialysis? – Jonathan Himmelfarb
2:30 p.m. Progress Toward Implantable Artificial Kidneys – Shuvo Roy
3:00 p.m. Cure Is the Best Treatment: Genome Editing – Jeremy Duffield
3:30 p.m. Making Sure the Patient Perspective Is Heard: The Kidney Health Initiative
Patient and Family Partnership Council – Leigh-Ann Williams

New Directions and Strategies to Improve Hypertension and Pain Management in CKD .................................................................W415 Valencia
Moderators: Linda Awdishu, Adriana Hung
2:00 p.m. It’s in the Genes: The Knowns and Unknowns of Hypertension and CKD Progression in African American Patients – Carol Horowitz
2:30 p.m. Implementation of a Genomics Program to Guide Optimal Selection of Antihypertensive Medications – Rhonda Cooper-DeHoff
3:00 p.m. Get Smart: Using Pharmacogenomics in CKD Hypertension Management – Michael Eadon
3:30 p.m. Improving Effectiveness and Safety of Opioid Use Through Pharmacogenomics-Guided Therapy – D. Max Smith

Choose Your Own Adventure: Nephrology Career Paths .........................................................................................................W314
Moderators: Stanley Crittenden, Tejas Desai
2:00 p.m. The Research Nephrologist – Opeyemi Olabisi
2:10 p.m. The Private Practitioner – Timothy Pfleiderer
2:20 p.m. The Clinician Educator – Kenar Jhaveri
2:30 p.m. The Nephrologist Business Leader – Mahesh Krishnan
2:40 p.m. The Nephrologist in Industry – Yasmin Brahmbhatt
2:50 p.m. The Nephrologist in Government – Susan Mendley
3:00 p.m. Panel Discussion

Thursday, November 3, 4:30 p.m. – 6:00 p.m.

Autosomal Dominant Tubulointerstitial Kidney Disease:
New Diagnostics and Therapies .................................................................WF1 Tangerine
Moderators: Anthony Bleyer, Ronak Lakhia
4:30 p.m. Landscape of REN Mutations – Martina Zivna
4:50 p.m. UMOD Disease Genetics and Models – Luca Rampoldi
5:10 p.m. MUC1 Biology and Models – Anna Greka
5:30 p.m. Kidney Plasticity Revealed Through Reversal of PKD in Mice – Stefan Somlo

Impact of MicroRNAs and Circular RNAs on the Pathogenesis and Prognosis of Glomerular Diseases.................................................................W304
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Vineet Gupta, Francesco Schena
4:30 p.m. MicroRNAs in Membranous Nephropathy and FSGS – Mario Schiffer
4:50 p.m. MicroRNAs in IgA Nephropathy – Izabella Pawluczyk
5:10 p.m. MicroRNAs in Diabetic Nephropathy – Maurice Fluitt
5:30 p.m. Circular RNAs and MicroRNAs in Lupus Nephritis – Jeffrey Kopp
Implementing the Race-Free eGFR Equations in Clinical Practice:
Where Are We Now? ................................................................. WF2 Tangerine
Support is provided by an educational grant from Chinook Therapeutics, Inc.
Moderators: Cynthia Delgado, Neil Powe

4:30 p.m. Adoption of the Race-Free Equations: Where Are We Now? – Joseph Vassalotti
4:50 p.m. New Approaches to Medication-Related Decision Making After Taskforce Recommendations – Thomas Nolin
5:10 p.m. Effect of 2022 CKD-EPI Equation on Donor Evaluation and Kidney Transplant Candidacy – John Friedewald
5:30 p.m. Cystatin C Barriers and Facilitators to Widespread Implementation in Practice – Amy Karger

Why Allografts Fail: Clinical, Histopathological, and Molecular Approach to Chronic Allograft Injury, Including the Barbara T. Murphy Endowed Lectureship .......... WF3 Tangerine
ASN gratefully acknowledges Verici Dx, Renalytix, and the American Society of Transplantation for supporting this lectureship.
Moderators: Roy Bloom, Mark Haas

4:30 p.m. Improving Kidney Graft Long-Term Outcomes: Lessons Learned and New Perspectives: The Barbara T. Murphy, MB BAO BCh, Endowed Lectureship – Roslyn Mannon
4:50 p.m. Molecular Approaches to Chronic Allograft Injury – Valeria Mas
5:10 p.m. Update to Banff Histopathological Diagnosis of Chronic Allograft Injury – Michael Mengel
5:30 p.m. Contributions of Antibody-Mediated and Cell-Mediated Alloimmunity to Chronic Graft Injury – Peter Nickerson

European Nephrology Highlights: Updates from the 2022 ERA Congress ......................... W224
ASN thanks the European Renal Association (ERA) for assistance with this session.
Moderators: Serhan Tuglular, Christoph Wanner

4:30 p.m. Basic Science and Translational Nephrology – Marianne Verhaar
4:50 p.m. Epidemiology and Clinical Nephrology – Kitty Jager
5:10 p.m. ESKD and Dialysis – Giovanni Gambaro
5:30 p.m. Kidney Transplantation – Andreas Kronbichler

Program is subject to change.
Thursday, November 3, 4:30 p.m. – 6:00 p.m.

Oral Abstract Sessions

AKI Research: Prediction, Diagnosis, Recovery ................................................................. W230
Moderators: Katja Gist, Sarah Huen
4:30 p.m. TH-OR01 Clonal Hematopoiesis of Indeterminate Potential Is Associated With a Higher Risk of Incident AKI – Caitlyn Vlasschaert
4:39 p.m. TH-OR02 Leveraging AKI Recovery Patterns Reveals a Genome-Wide Significant Variant Associated With a Higher Risk of Non-Resolving AKI – Pavan Bhatraju
4:48 p.m. TH-OR03 Associations of Blood Mitochondrial DNA Copy Number With Risk of AKI After Cardiac Surgery – Vasantha Jotwani
4:57 p.m. TH-OR04 Oral Anticoagulant Therapy and Risk of Kidney Disease: A Nationwide Cohort Study – Ané Emilie Vestergaard
5:06 p.m. TH-OR05 Urine NGAL for AKI Screening Following Triggering of Baby NINJA (Nephrotoxic Injury Negated by Just-in-Time Action) – Cara Slagle
5:15 p.m. TH-OR06 Development of a Machine Learning Algorithm to Predict Major Adverse Kidney Events (MAKE) After Hospitalization – Jay Koyner
5:24 p.m. TH-OR07 Machine Learning Models Uncover Subphenotypes of AKI With Unique Signatures That Associate With Differing Clinical Outcomes – George Vasquez-Rios
5:33 p.m. TH-OR08 Machine Learning for Development of a Real Time AKI Risk Prediction Model in ICU With External Validation and Federated Learning at Five Medical Centers: From Model Development to Clinical Application – Chun-Te Huang
5:42 p.m. TH-OR09 AKI Flagger: A Standardized AKI Definition Tool for Electronic Health Record (EHR) Research – Abinet Aklilu
5:51 p.m. TH-OR10 Novel Urinary Proteins Differentiate Sub-Phenotypes in Patients With Sepsis-Induced AKI – Ian Stanaway

Dialysis: Patient-Centered Interventions and Outcomes .................................................. W414
Moderators: Sahir Kalim, Mariana Murea
4:30 p.m. TH-OR11 Role of the Pre-Hemodialysis Lung Ultrasound for Dry-Weight Assessment and Intradialytic Hypotension Risk Prediction – Giulia Palazzini
4:39 p.m. TH-OR12 Application of Intradialytic Magnetic Resonance Imaging and Spectroscopy Demonstrates Hemodialysis-Related Acute Brain Injury – Dickson Wong
4:48 p.m. TH-OR13 Intradialytic Exercise Is Associated With Lower Mortality Risk in Hemodialysis Patients – Pedro Martins
4:57 p.m. TH-OR14 0.075% Capsaicin Lotion for the Treatment of Peripheral Neuropathy in ESRD Patients: A Multicenter Randomized Double-Blind Placebo-Controlled, Cross-Over Trial – Parinada Kittidanairuk
5:06 p.m. TH-OR15 Preferences for End-of-Life Care Among Dialysis Patients: A Discrete Choice Experiment – Ania Filus
5:15 p.m. TH-OR16 DIALIZE China: A Phase 3b Study to Reduce Pre-Dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Subjects – June Zhao
5:24 p.m. TH-OR17 Effect of ESRD Treatment Choices (ETC) on Home Dialysis Utilization Among Incident Dialysis Patients – Kirsten Johansen
5:33 p.m. TH-OR18 The Effects of Implementing a Home Dialysis Project ECHO – Christopher Chan
5:42 p.m. TH-OR19 High-Flow Arteriovenous Fistula and Myocardial Fibrosis in Hemodialysis Patients With Non-Contrast Cardiac Magnetic Resonance Imaging – Jwa-kyung Kim
5:51 p.m. TH-OR20 Biofunctionalized Vascular Access Graft Enhanced Patency and Endothelialization in a Pig Arteriovenous (AV) Model – Prakash Parthiban Selvakumar
Thursday, November 3, 4:30 p.m. – 6:00 p.m.

**Hypertension and CVD: Epidemiology, Risk Factors, Prevention** ......................................................... W240
Moderators: Ruth Dubin, Sandra Taler

4:30 p.m.  **TH-OR21**  Hypertension Population Within an Integrated Healthcare System – Victor Kim

4:39 p.m.  **TH-OR23**  Influence of Baseline Diastolic BP (DBP) on the Effects of BP Lowering on Cardiovascular (CV) Outcomes: A Meta-Analysis of NIH BP Trials – Amara Sarwal

4:48 p.m.  **TH-OR24**  Sex Difference in Cardiovascular Risk in Non-CKD and CKD: NHANES 1999-2018 – Ester Oh

4:57 p.m.  **TH-OR25**  Associations of Impaired Kidney Function With Cerebral Small Vessel Disease and Cognitive Disorders: Findings From the Framingham Heart Study – Dearbhla Kelly

5:06 p.m.  **TH-OR26**  Nutritional Status and Cardioirenal Syndrome: Associations of Protein-Energy Wasting and Abdominal Obesity With the Risk of Heart Failure in CKD – Tejita Agarwal

5:15 p.m.  **TH-OR27**  Role of Human T Cells in Hypertension and Hypertensive Organ Damage – Johannes Stegbauer

5:24 p.m.  Invited Lecture  Undiagnosed Primary Hyperaldosteronism and Renal Implications – Gordon Williams

**Pediatric Nephrology: From Bench to Bedside** ....................................................................................... W307
Moderators: Detlef Bockenhauer, Michelle Rheault

4:30 p.m.  **TH-OR28**  HLA-DR/DQ Single Molecule Eplet Mismatch and Formation of De Novo Donor-Specific Anti-HLA Antibodies After Kidney Transplantation in Children – Vaka Sigurjonsdottir

4:39 p.m.  **TH-OR29**  A Multi-Population Polygenic Risk Score for Pediatric Steroid Sensitive Nephrotic Syndrome Is Correlated With Disease Age at Onset – China Nagano

4:48 p.m.  **TH-OR30**  Prevalence and Persistence of CKD and Hypertension 36 Months Post-Cisplatin in Children – Kelly McMahon

4:57 p.m.  **TH-OR31**  Rapid Correction of Hypernatremia Is Not Associated With Mortality or Neurological Morbidity in Children: The Correcting Hypernatremia in Children Study – Madeleine Didsbury

5:06 p.m.  **TH-OR32**  Intradialytic Hypotension and Mortality in Children and Young Adults – Xixi Zhao

5:15 p.m.  **TH-OR33**  Urinary DKK3 Predicts Short-Term eGFR Decline and Nephroprotective Efficacy of Antihypertensive Therapy in Children With CKD: Findings From the 4C Study and ESCAPE Trial – Franz Schaefler

5:24 p.m.  **TH-OR34**  Nedosiran in Patients With Primary Hyperoxaluria 1: Interim Results From an Extension Trial (PHYOX3) – John Lieske

5:33 p.m.  **TH-OR35**  Ciliary ARL13B Is a Major Driver of Kidney Cystogenesis – Robert Van Sciver

5:42 p.m.  **TH-OR36**  Arginine Metabolism Has a Pivotal Role in Cystogenesis of Tuberous Sclerosis Complex (TSC) and Its Inhibition Alleviates TSC Cyst Overload – Morris Nechama

5:51 p.m.  **TH-OR37**  Correction of Pkd1 Loss-of-Function Model by Targeted Therapeutic Gene Transfer – Almira Kurbegovic

Program is subject to change.
Technology-Based Approaches in Nephrology

Moderators: Joseph Bonventre, Patrick Murray

4:30 p.m.  TH-OR38 Transdermal Glomerular Filtration Rate Measurement: Clinical Results From a Pilot Multicenter Study Establishing Feasibility and Efficacy – Richard Dorshow

4:39 p.m.  TH-OR39 Evaluation of Renal Blood Flow Using 64Cu-ATSM PET – Naoki Takahashi

4:48 p.m.  TH-OR40 Targeted Isolation of Urine-Derived Renal Tubular Cells for Personalised Medicine – Chutong Zhong

4:57 p.m.  TH-OR41 CODEX Multiplex Imaging Unlocks Unique Cell Types, States, and Niches in Health and Disease – Daria Barwinska

5:06 p.m.  TH-OR42 Super-Resolution Microscopy in Clinical Specimens Using Conventional Widefield Microscopes – Dominik Kylies

5:15 p.m.  TH-OR43 Analyzing Cell Type-Specific Dynamics of Metabolism in Kidney Repair – Ton Rabelink

5:24 p.m.  TH-OR44 High Resolution Spatially Resolved Transcriptomic Atlas of Kidney Injury and Repair With Direct RNA Hybridization-Based In Situ Sequencing – Haojia Wu

5:33 p.m.  TH-OR45 Genome-Wide CRISPR Screen Reveals That Elamipretide (SS-31) Mediated PLSCR3 Activation Mitigates Mitochondrial Dysfunction During AKI – Josie Silvaroli

5:42 p.m.  TH-OR46 Downregulation of Syndecan-1 and Alternative Complement in Renal Proximal Tubular Epithelial Cells by Crotamine/Sirna Complexes – Jacob van den Born

5:51 p.m.  TH-OR47 #AskRenal: Use of an Automated Twitter Account to Crowdsources Nephrology Queries – Jade Teakell

Transplantation: Basic Research

Moderators: Xun-Rong Luo, Jonathan Maltzman

4:30 p.m.  TH-OR48 Using Three-Dimensional Imaging and Single-Cell Transcriptomics to Interrogate Human Kidney Lymphatics in Transplant Rejection – Daniyal Jafree

4:39 p.m.  TH-OR49 Critical Role of CD74 in Immune Regulation and Allograft Tolerance – Zhabiz Solhjou

4:48 p.m.  TH-OR50 Single Nuclei RNA-Sequencing Identifies Distinct Immune Profiles in Interstitial Fibrosis and Tubular Atrophy Human Allografts Following 15 Months Post-Transplantation – Thomas Roussele

4:57 p.m.  TH-OR51 A Single-Nucleus RNA-Sequencing of Human Kidney Transplant Biopsies Identifies a Novel Role of Pericytes and Endothelium in Cellular Rejection – Ahmad Halawi

5:06 p.m.  TH-OR52 IL-2/Anti-IL-2 Immune Complex Attenuates Cold Ischemia-Reperfusion Injury in Kidney Transplantation by Expanding Regulatory T Cells – Ga Young Heo

5:15 p.m.  TH-OR53 Mobilizing MHC Class Ib-Restricted Regulatory CD8 T Cells (CD8 Treg) With a Peptide Agonist Promotes Allograft Tolerance in a Fully Mismatched Mouse Kidney Transplant Model – John Choi

5:24 p.m.  TH-OR54 Targeting the Archetypal Innate Immune Receptor Integrin CD11b Prolongs Kidney Allograft Survival in Nonhuman Primates (NHPs) – Abbas Dehnadi

5:33 p.m.  TH-OR55 Molecular and Cellular Mechanisms of Lipocalin-2-Mediated Renoprotection in Kidney Transplantation – Anna Pfefferkorn

5:42 p.m.  TH-OR56 Phascolarctobacterium-Producing Propionate and Acute Rejection Among Kidney Transplant Recipients – Hyunjeong Cho

5:51 p.m.  TH-OR57 Cytomegalovirus-Responsive CD4 T Cells Exhibit a Stable, Cytotoxic Phenotype During the First Year After Solid Organ Transplant – Ayah Ahmad
### Poster Sessions

**Thursday, November 3 | West Exhibit Hall D**

<table>
<thead>
<tr>
<th>Poster Topics</th>
<th>Board #s</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIDDK and Informational Posters</td>
<td>INFO01–40</td>
</tr>
<tr>
<td>Educational Research</td>
<td>001–021</td>
</tr>
<tr>
<td>AKI: Biomarkers, Risk Factors, Treatments, Outcomes</td>
<td>022–081</td>
</tr>
<tr>
<td>AKI: Mechanisms - I</td>
<td>082–141</td>
</tr>
<tr>
<td>CKD-MBD: Targets and Outcomes</td>
<td>142–176</td>
</tr>
<tr>
<td>Diabetic Kidney Disease: Basic - I</td>
<td>177–227</td>
</tr>
<tr>
<td>Diabetic Kidney Disease: Clinical - I</td>
<td>228–255</td>
</tr>
<tr>
<td>Vascular Access: From Biology to Managing Complications</td>
<td>256–303</td>
</tr>
<tr>
<td>Fluid, Electrolyte, and Acid-Base Disorders: Basic</td>
<td>304–354</td>
</tr>
<tr>
<td>Genetic Diseases of the Kidneys: Cystic - I</td>
<td>355–414</td>
</tr>
<tr>
<td>Glomerular Diseases: Inflammation and Fibrosis</td>
<td>415–439</td>
</tr>
<tr>
<td>Glomerular Diseases: Podocytopathies and Nephrotic Syndromes</td>
<td>440–471</td>
</tr>
<tr>
<td>Glomerular Diseases: Clinical, Outcomes, Trials - I</td>
<td>472–528</td>
</tr>
<tr>
<td>Pathology and Lab Medicine</td>
<td>529–588</td>
</tr>
<tr>
<td>Hypertension and CVD: Epidemiology, Risk Factors, Prevention</td>
<td>589–635</td>
</tr>
<tr>
<td>Transplantation: Basic</td>
<td>636–655</td>
</tr>
<tr>
<td>Anemia and Iron Metabolism</td>
<td>656–705</td>
</tr>
<tr>
<td>Diversity and Equity in Kidney Health - I</td>
<td>706–743</td>
</tr>
<tr>
<td>Sex and Reproductive Factors in Kidney Health</td>
<td>744–767</td>
</tr>
<tr>
<td>Voices, Choices, and Outcomes of Older Adults with CKD</td>
<td>768–799</td>
</tr>
<tr>
<td>Health Maintenance, Nutrition, Metabolism</td>
<td>800–851</td>
</tr>
<tr>
<td>CKD: Epidemiology, Risk Factors, Prevention - I</td>
<td>852–900</td>
</tr>
<tr>
<td>COVID-19: Long COVID</td>
<td>901–913</td>
</tr>
<tr>
<td>COVID-19: Vaccines and Outcomes ESRD/KTR</td>
<td>914–963</td>
</tr>
<tr>
<td>Late-Breaking Clinical Trials</td>
<td>964–996</td>
</tr>
<tr>
<td>NIDDK KUH Summer Undergraduate Research Program</td>
<td>997–1006</td>
</tr>
</tbody>
</table>

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.

### Welcome Reception

**Thursday, November 3**

6:00–7:00 p.m.

West Exhibit Hall D

*The Welcome Reception is supported by Fresenius Medical Care Renal Pharmaceuticals.*
You are invited to a hands-on review session of all the digital slides from the Renal Biopsy: Clinical Correlations session vignettes prior to Saturday, November 5, when the final diagnoses are discussed in depth and answers to the cases are distributed. Biopsy materials are available with renal pathologists onsite to direct your study of the cases and to provide individual instruction. There is no fee to visit the Pathology Room; however, space is limited and available on a first-come, first-served basis.

ASN thanks the Renal Pathology Society for assistance with the Digital Pathology Room.
ASN invites you to take part in the ASN Career Fair. Connect with employers and find your next nephrology opportunity. All Annual Meeting registrants are welcome to participate for free!

Be on the lookout for the ASN Featured Employers Guide which will include open positions from top employers. It will be sent directly to your email after Kidney Week.

ASN Career Fair
Meet face-to-face with top employers looking to hire!

November 3–5
9:30 a.m. – 2:30 p.m.
West Exhibit Hall D

Take charge of your career! Upload or update your resume on the ASN Career Center.

Get your resume in front of employers hiring nephrology professionals who search the database.

Search jobs that are posted right from your smartphone or tablet.

Be the first to get job alerts when a job that meets your criteria is posted.

Gain resume writing tips and how to prepare for an interview.

Visit careers.asn-online.org to get started!
DAY-AT-A-GLANCE
Friday, November 4

8:00 a.m. – 9:30 a.m.
Plenary: ASN President’s Medal, Barbara T. Murphy Trailblazer Award, John P. Peters Award, Donald W. Seldin Young Investigator Award and Address, State-of-the-Art Lecture ................................................................. W415 Valencia

9:30 a.m. – 2:30 p.m.
Morning Break (9:30 a.m. – 10:00 a.m.) ................................................................. West Exhibit Hall D
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.) ........................................ West Exhibit Hall D
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.) .................................. West Exhibit Hall D

10:30 a.m. – 12:30 p.m.
Basic/Clinical Science Sessions
Developing Personalized Medicine for Peritoneal Dialysis Patients ................................ WF2 Tangerine
Hypertension Is an Immune-Mediated Disease .......................................................... W311
Nephron Endowment and Links to Cessation of Nephrogenesis .................................. W240
New Insights into Paracellular Transport and Tight Junction Architecture in Kidney .... W230
Regulatory, Inflammatory B Cells and Autoantibodies: From Bench to Human Translation ................................................................. WF3 Tangerine

Clinical Practice Sessions
Nephrologists as Primary Care Physicians .............................................................. WF1 Tangerine
Potpourri of Infection-Related Glomerular Diseases ................................................. W304
Update on Treatment Considerations in Nephrolithiasis ........................................... W414

Translational Sessions
Biomarkers and Diabetic Kidney Disease ................................................................. W224
Throw It into Reverse: AKI Science at the Bedside ..................................................... W320 Chapin

Oral Abstract Session
High-Impact Clinical Trials ...................................................................................... W415 Valencia

Other Event
Fellows-in-Training Bowl: Semi-Finals and Finals .................................................. West Exhibit Hall D

12:45 p.m. – 1:45 p.m.
Educational Symposia (Hyatt Regency Orlando) – Doors open at 12:30 p.m.
Current and Future Approaches to the Diagnostic Assessment and Management of AKI in Patients with Cirrhosis ........................................ Regency Ballroom R
Hyperphosphatemia Management in Adults Treated with Dialysis for Kidney Failure: Old Lessons, New Directions ................................................ Regency Ballroom S
Update on the Management of Recurrent Hyperkalemia Associated with RAAS Inhibitors in Patients with CKD and ESRD ........................................ Regency Ballroom T

2:00 p.m. – 4:00 p.m.
Basic/Clinical Science Sessions
Best of ASN Journals 2022: JASN, CJASN, and Kidney360 ........................................ W314
Emerging Therapeutic Approaches in AKI: New Targets and How to Reach Them .... W308
Extracellular Matrix Pathobiology in CKD and Alport Syndrome ............................. WF1 Tangerine
Lifestyle Interventions: Findings from Recent Trials ................................................ W304
Macula Densa Front and Center ................................................................................ W230
Novel Mechanisms of BP Regulation .................................................................. W311
Pediatric AKI Is More Than Just a (Creatinine) Number: Challenges and Advances to Care .... W240
2:00 p.m. – 4:00 p.m.

**Basic/Clinical Science Sessions (cont.)**

Regenerating the Diabetic Kidney ................................................................. W224
Vascular Access: Promising Dialysis Innovation to Ensure Equity in Opportunities and Care Delivery ................................................................. WF2 Tangerine

**Clinical Practice Sessions**

Evidence-Based Management of Septic AKI,
  Including the Burton D. Rose Endowed Lectureship .......................... W307
Glomerulonephritis in Systemic Diseases: Emphasis on Emerging Therapies and Prognosis ................................................................. W415 Valencia
Improving Patient Care at the Transition to Kidney Failure:
  Insights from USRDS and DOPPS ...................................................... W320 Chapin

**Translational Sessions**

Modern Scientific Breakthroughs: Are COVID-19 Vaccines Enough for
  Kidney Transplant Recipients? ............................................................. WF3 Tangerine
Molecular Diagnostics in Interpretation of Native and Transplant Kidney Biopsies .................................................. W315
Novel Strategies for Preventing End-Organ Damage and Dysfunction from CKD-MBD,
  Including the Jack W. Coburn Endowed Lectureship .......................... W414

4:00 p.m. – 4:30 p.m.

Afternoon Break ............................................. West Lobby D, West Lobby E/F, W415 Valencia Foyer, W320 Foyer

4:30 p.m. – 6:00 p.m.

**Basic/Clinical Science Session**

Where It Begins: Complex Genetic Drivers of Kidney Phenotypes .............. WF1 Tangerine

**Clinical Practice Sessions**

AKI in Cirrhosis: Will Personalized Management Improve Outcomes? ........ W224
Leveraging Social Media to Create, Learn, Teach, Advocate, and Dispel Misinformation .................................................. W304
Trauma Behind My Smile: Better Access to Behavioral Health Resources During the Transplant Process, Including the Celeste Castillo Lee Endowed Lectureship .......... WF3 Tangerine

**Translational Session**

Advancing Clinical Trials for People with Kidney Diseases: An Overview .......... WF2 Tangerine

**Oral Abstract Sessions**

Advances in Mineral Metabolism and Nephrolithiasis ................................ W314
AKI Research: Mechanisms ................................................................. W230
CKD: Clinical Outcomes, Trials, Mechanistic Insights .......................... W307
Diabetic Kidney Disease: From Single Cell to Outcomes ....................... W240
Fluid, Electrolyte, and Acid-Base Disorders Research ............................. W308
Glomerular Diseases: From Bench to Bedside ........................................ W414

**Other Event**

Building Capacity to Collect Patient Preferences Information for Innovative Kidney Devices ........ W315

**Topical Chats**

IMGs and Immigration Challenges: The Great Burnout .......................... W221A
The Renal Biopsy Report: What Nephrologists Need for Optimal Patient Care .................................................. W221E

Download the meeting app or scan the QR code for more details and updates.
Friday, November 4, 8:00 a.m. – 9:30 a.m.

Plenary: ASN President’s Medal, Barbara T. Murphy Trailblazer Award, John P. Peters Award, Donald W. Seldin Young Investigator Award and Address, State-of-the-Art Lecture

8:00 a.m.  ASN President’s Medal – Patrick Gee, Glenda Roberts, David Rush
8:10 a.m.  Barbara T. Murphy Trailblazer Award – Julie Ingelfinger
8:20 a.m.  John P. Peters Award – Sharon Anderson
8:30 a.m.  Donald W. Seldin Young Investigator Award and Address “Unexpected Roles for Renal Olfactory Receptors” – Jennifer Pluznick
9:00 a.m.  State-of-the-Art Lecture “Making the Impossible Possible: First-In-Human Clinical Grade Kidney Xenotransplant” – Jayme Locke

Friday, November 4, 10:30 a.m. – 12:30 p.m.

Developing Personalized Medicine for Peritoneal Dialysis Patients

Moderators: Jeffrey Perl, Isaac Teitelbaum
10:30 a.m. Developing Personalized Medicine for Dialysis Patients – Rajnish Mehrotra
11:00 a.m. Genetic Studies and Precision Medicine in Dialysis Patients – Olivier Devuyst
11:30 a.m. Individualizing Dialysis Therapy: Identifying the Patient at Risk – Claus Peter Schmitt
12:00 p.m. Cytoprotection in Peritoneal Dialysis – Rebecca Herzog

Hypertension Is an Immune-Mediated Disease

Moderators: Susan Gurley, Jennifer Pluznick
10:30 a.m. Is Hypertension an Immune Disease? – David Harrison
11:00 a.m. Monocytes as Immune Targets in Arterial Hypertension – Philip Wenzel
11:30 a.m. Minocycline as a Treatment of Resistant Hypertension: Results of a Clinical Study – Eileen Handberg
12:00 p.m. Role of Immune Cells in Hypertension – Ernesto Schiffrin

Nephron Endowment and Links to Cessation of Nephrogenesis

Moderators: Jennifer Charlton, Greg Dressler
10:30 a.m. Progenitor Translatome Changes End Nephrogenesis – Raphael Kopan
11:00 a.m. Prolongation of Mammalian Nephrogenesis by Excess Fetal Glial Cell Line-Derived Neurotrophic Factor – Satu Kuure
11:30 a.m. Lin28 and Let-7 Regulate Cessation of Murine Nephrogenesis – Jihan Osborne
12:00 p.m. Chromatin Changes in Nephron Progenitors – Samir El-Dahr

New Insights into Paracellular Transport and Tight Junction Architecture in Kidney

Moderators: Vivek Bhalla, Alan Yu
10:30 a.m. Claudin-2 and -12 Form Independent Complementary Pores Required to Maintain Calcium Homeostasis – R. Todd Alexander
11:00 a.m. Interaction Between Epithelial Sodium Channel (ENaC) and Claudin-8 Modulates Paracellular Permeability in Collecting Duct – Ali Sassi
11:30 a.m. Calcium Sensing and Claudin Regulation in Kidney – Henrik Dimke
12:00 p.m. Role of Claudin-10 Splice Variants in Paracellular Transport in Kidney and Underlying HELIX Syndrome – Dorothee Günzel
### Regulatory, Inflammatory B Cells and Autoantibodies: From Bench to Human Translation

**WF3 Tangerine**  
**Moderators:** Mohammed Javeed Ansari, Paolo Cravedi  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.</td>
<td>Development of Antigen-Specific Memory B Cells During Alloimmunity</td>
<td>Stanley Jordan</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>B Cell Cytokine Balance Early Post-Transplantation Is a Predictive Biomarker for Post-Transplant Outcomes</td>
<td>Aravind Cherukuri</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Human Bregs Expressing TIM-1 and TIGIT Exhibit Regulatory Activity That Correlates with Kidney Transplant Outcomes</td>
<td>SangKon Oh</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Autoantibodies Contribute to Microvascular Rarefaction and Progressive Kidney Dysfunction</td>
<td>Marie-Josee Hebert</td>
</tr>
</tbody>
</table>

### Nephrologists as Primary Care Physicians

**WF1 Tangerine**  
**Moderators:** Jeffrey Berns, Mallika Mendu  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.</td>
<td>Lipid Management in Patients with Kidney Diseases</td>
<td>Roy Mathew</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Immunization in CKD</td>
<td>Snigdha Reddy</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Cancer Screening in Dialysis Patients</td>
<td>Mitchell Rosner</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Approach to Depression Screening and Treatment in Kidney Diseases</td>
<td>Susan Hedayati</td>
</tr>
</tbody>
</table>

### Potpourri of Infection-Related Glomerular Diseases

**W304**  
*Support is provided by an educational grant from Travere Therapeutics, Inc.*  
**Moderators:** Ali Poyan-Mehr, Anjali Satoskar  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.</td>
<td>Epidemiology, Bacteriology, and Patterns of Glomerular Injury in Bacterial Infection-Related Glomerulonephritis</td>
<td>Joseph Gaut</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Clinical Manifestations, Management, and Outcomes of Bacterial Infection-Related Glomerulonephritis</td>
<td>Samir Parikh</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Viral-Associated Glomerular Diseases: Patterns of Glomerular Injury and Pathogenesis</td>
<td>Christina Wyatt</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Clinical Manifestations and Management of Viral-Associated Glomerular Diseases</td>
<td>Meghan Sise</td>
</tr>
</tbody>
</table>

### Update on Treatment Considerations in Nephrolithiasis

**W414**  
**Moderators:** Cynthia Denu-Ciocca, Andrew Schwaderer  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.</td>
<td>Using Next Generation Sequencing to Identify Monogenic Urinary Stone Disease Patients</td>
<td>Peter Harris</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Dietary Modification to Prevent Stone Recurrence: Does It Work?</td>
<td>Megan Prochaska</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Clinical Pearls for the Use of 24-Hour Urine Studies to Assess Stone Risk</td>
<td>John Asplin</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Oxalate and Adverse Health Effects: More Than Just Stones?</td>
<td>Felix Knauf</td>
</tr>
</tbody>
</table>

### Biomarkers and Diabetic Kidney Disease

**W224**  
**Moderators:** Steven Coca, Wenjun Ju  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.</td>
<td>Albuminuria and GFR</td>
<td>Hiddo Heerspink</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Circulating Protein Markers</td>
<td>Monika Niewczas</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Epigenetic Markers</td>
<td>Assam El-Osta</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Machine Learning</td>
<td>Laura Mariani</td>
</tr>
</tbody>
</table>

*Program is subject to change.*
Friday, November 4, 10:30 a.m. – 12:30 p.m.

**Throw It into Reverse: AKI Science at the Bedside**.....................................................W320 Chapin
Moderators: Eryn Dixon, Joachim Ix
10:30 a.m.  **Updates from the Kidney Precision Medicine Project** – Jonathan Himmelfarb
11:00 a.m.  **Mechanistic Markers Have Transformed Oncology, So What’s on the Horizon for AKI?** – Shruti Gupta
11:30 a.m.  **SGLT2 Inhibitors and AKI Protection: Signal, Noise, So What?** – Sarah Huen
12:00 p.m.  **Advances in Imaging to Assess Kidney Health and Reserve** – Anand Srivastava

**High-Impact Clinical Trials**..............................................................................................W415 Valencia
Please check the Kidney Week app or the ASN website for session details.

**Fellows-in-Training Bowl: Semi-Finals and Finals**...................................................West Exhibit Hall D
Support is provided by Chinook Therapeutics, Inc.
Note: Continuing education credits are not being offered for this activity.

Friday, November 4, 12:45 p.m. – 1:45 p.m.

**Educational Symposia (Hyatt Regency Orlando)** – Doors open at 12:30 p.m.
Lunch is provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants.

**Current and Future Approaches to the Diagnostic Assessment and Management of AKI in Patients with Cirrhosis**....................................................Regency Ballroom R
Support is provided by an educational grant from Mallinckrodt Pharmaceuticals.
12:45 p.m.  **Introduction** – Kathleen Liu (Moderator)
12:55 p.m.  **Current Approach to the Diagnostic Evaluation of Patients with AKI and Cirrhosis** – Chirag Parikh
1:15 p.m.  **Evidence-Based Management of Hepatorenal Syndrome with AKI** – Florence Wong
1:35 p.m.  **Questions and Answers**

**Hyperphosphatemia Management in Adults Treated with Dialysis for Kidney Failure: Old Lessons, New Directions**.......................................................Regency Ballroom S
Support is provided by an educational grant from Akebia Therapeutics, Inc.
12:45 p.m.  **Introduction** – Ebele Umeukeje (Moderator)
12:55 p.m.  **Phosphorus Metabolism in Kidney Failure: How Biology Informs Medication Therapy** – Sagar Nigwekar
1:15 p.m.  **Diet Strategies to Improve Hyperphosphatemia Independent of and Integrated with Medication Therapy** – Kathleen Hill Gallan
1:35 p.m.  **Questions and Answers**

**Update on the Management of Recurrent Hyperkalemia Associated with RAAS Inhibitors in Patients with CKD and ESRD**..................................................Regency Ballroom T
Support is provided by an educational grant from CSL Vifor.
12:45 p.m.  **Introduction: Rationale Behind Using RAAS Inhibitors in Patients with CKD and CVD** – Alan Pao (Moderator)
12:55 p.m.  **Advances in Therapies for Recurrent Hyperkalemia in Patients with CKD and ESRD** – Charles Wingo
1:15 p.m.  **Update on Potassium Balance and the Molecular Mechanism Underlying Hyperkalemia** – Chou-Long Huang
1:35 p.m.  **Questions and Answers**
Best of ASN Journals 2022: JASN, CJASN, and Kidney360.................................W314
ASN thanks JASN, CJASN, and Kidney360 for assistance with this session.
Moderators: Michael Allon, Mark Knepper, Rajnish Mehrotra
2:00 p.m. Advances in Glomerular Disease – Katalin Susztak
2:40 p.m. Caring for Patients with Kidney Failure – Dana Miskulin
3:20 p.m. New Insights into Hypertension and CVD – Steven Crowley

Emerging Therapeutic Approaches in AKI: New Targets and How to Reach Them.........W308
Moderators: Monica Chang Panesso, Prabhleen Singh
2:00 p.m. Senolytic Treatment to Promote Kidney Repair – David Ferenbach
2:30 p.m. Mitochondrial Therapy for AKI – Amandeep Bajwa
3:00 p.m. Nanotherapeutics in Kidney Biology – Eun ji Chung
3:30 p.m. Clinical Potential of Nanoparticles in AKI – Daniel Heller

Extracellular Matrix Pathobiology in CKD and Alport Syndrome.......................WF1 Tangerine
Moderators: Tomoko Horinouchi, Roser Torra
2:00 p.m. Update on the Alport Syndrome Community, Research, and Education Efforts – B. Andre Weinstock
2:30 p.m. Kidney Basement Membrane Composition, Regulators, and Human Disease Associations – Rachel Lennon
3:00 p.m. Developing Gene Editing Approaches in Alport Syndrome – Jeffrey Miner
3:30 p.m. Therapeutic Development in Alport Syndrome – Oliver Gross

Lifestyle Interventions: Findings from Recent Trials..........................................W304
Moderators: Devika Nair, Daniel Weiner
2:00 p.m. Mobilizing a Multidisciplinary Team to Conduct a Lifestyle Intervention in Patients with CKD – Erin Howden
2:30 p.m. Sit Less, Move More! Targeting Sedentary Behavior in Patients with CKD – Srinivasan Beddhu
3:00 p.m. Exercise to Improve Outcomes in CKD: Evidence for Benefit? – Thomas Wilkinson
3:30 p.m. Barriers and Facilitators to Adopting Lifestyle Interventions: A Patient’s Perspective – Curtis Warfield

Macula Densa Front and Center .............................................................................W230
Moderators: Branko Braam, Clintoria Williams
2:00 p.m. Macula Densa Cells and Tubuloglomerular Feedback: The Basics – Scott Thomson
2:30 p.m. Unique Gene Expression Profile of Macula Densa Cells – Lihe Chen
3:00 p.m. Novel Macula Densa SGLT1-NOS1 Signaling Pathway and Its Implications – Jie Zhang
3:30 p.m. New Features of Macula Densa Cells: From Maculapodia to Protein Synthesis Powerhouse – Janos Peti-Peterdi

Program is subject to change.
Friday, November 4, 2:00 p.m. – 4:00 p.m.

Novel Mechanisms of BP Regulation ............................................................................................. W311
Moderators: Keyona King, Aaron Polichnowski
2:00 p.m. Roles of WNK4 and SPAK in Potassium-Mediated Dephosphorylation of the NaCl Cotransporter – David Ellison
2:30 p.m. Hypothalamic Control of Sympathetic Nerve Activity in Hypertension – Sean Stocker
3:00 p.m. Mechanisms by Which Fructose Influences BP – Richard Johnson
3:30 p.m. Elucidating Immune Mechanisms Causing Hypertension During Pregnancy – Kedra Wallace

Pediatric AKI Is More Than Just a (Creatinine) Number:
Challenges and Advances to Care .................................................................................................. W240
Moderators: Tahagod Mohamed, Rupesh Raina
2:00 p.m. Pediatric AKI: Another Example of How Children Are Not Little Adults – Jeffrey Fadrowski
2:30 p.m. Advances in the Prevention and Identification of Early AKI: The Role of Biomarkers and Artificial Intelligence – Shina Menon
3:00 p.m. Role and Impact of Quality Improvement Initiatives in Pediatric AKI – Stuart Goldstein
3:30 p.m. Kidney Prognosis of Children with AKI – Cherry Mammen

Regenerating the Diabetic Kidney ................................................................................................. W224
Moderators: Sharon Adler, Matthias Kretzler
2:00 p.m. Kidney Organoids for Disease Modeling – Nuria Montserrat
2:30 p.m. Immunomodulation versus Direct Repair – Lilach Lerman
3:00 p.m. Organoid Models for Studying Diabetic Nephropathy: Promises and Challenges – Yun Xia
3:30 p.m. Mitochondrial Transfer – Kei Fukami

Vascular Access: Promising Dialysis Innovation to Ensure Equity in Opportunities and Care Delivery .................................................................................................. WF2 Tangerine
Moderators: Anna Burgner, Monnie Wasse
2:00 p.m. Journey of Hemodialysis Access: The Patient Perspective – Caroline Wilkie
2:30 p.m. Cells to Polytetrafluoroethylene: How Biology Leads Us to New Technology in Vascular Access – Laisel Martinez
3:00 p.m. Visualizing Hemodialysis Vascular Access: Updates and Refreshers in Lessons from Radiology – Dheeraj Rajan
3:30 p.m. Shared Decision Making in Vascular Access: Practices to Achieve Equity and Personalized Care – Louise Moist
Evidence-Based Management of Septic AKI, Including the Burton D. Rose Endowed Lectureship

ASN gratefully acknowledges Wolters Kluwer (publisher of UpToDate), the Beth Israel Deaconess Medical Center Department of Medicine Foundation, the Rose Family, and several of Dr. Rose’s colleagues for supporting this lectureship.

Moderators: Jay Koyner, Blaithin McMahon

2:00 p.m. Fluid Management in Septic AKI: When, What Type, and How Much? The Burton D. Rose, MD, Endowed Lectureship – Kathleen Liu

2:30 p.m. Vasoactive Drugs in Septic Shock and AKI: Which Drugs to Use, and Which Parameters to Target? – Lui Forni

3:00 p.m. Corticosteroid Therapy in Sepsis: Current Recommendations – Marlies Ostermann

3:30 p.m. RRT in Septic AKI: When to Start, How to Dose, and When to Stop? – Ron Wald

Glomerulonephritis in Systemic Diseases: Emphasis on Emerging Therapies and Prognosis

Support is provided by an educational grant from Travere Therapeutics, Inc.

Moderators: Isabelle Ayoub, Dana Rizk

2:00 p.m. IgA Vasculitis Nephritis: New Insights into Prognosis and Treatment from a Large International Study – Evangeline Pillebout

2:30 p.m. Pathogenesis-Based Treatment Approaches to ANCA Glomerulonephritis and Vasculitis – David Jayne

3:00 p.m. Current Treatment of Cryoglobulinemic Glomerulonephritis and Vasculitis – David Saadoun

3:30 p.m. Treatment of Lupus Nephritis: Beyond the Usual Suspects – Liz Lightstone

Improving Patient Care at the Transition to Kidney Failure: Insights from USRDS and DOPPS

Moderators: Elaine Ku, Sri Lekha Tummalapalli

2:00 p.m. Initiation of Treatment for Kidney Failure: How COVID-19 Has Influenced Care Practices in the United States – James Wetmore

2:30 p.m. International Perspective: Optimal Preparation for Kidney Failure – Roberto Pecoits-Filho

3:00 p.m. United States Perspective: What Is the “Optimal Start” for Kidney Replacement Therapy? How Often Do We Achieve It? – Kirsten Johansen

3:30 p.m. Aligning Care to Improve Management of CKD Complications: From Before to After the Transition to Dialysis – Christian Combe

Modern Scientific Breakthroughs: Are COVID-19 Vaccines Enough for Kidney Transplant Recipients?

Moderators: Dianne McKay, Miklos Molnar

2:00 p.m. COVID-19: Tweaking Immune Responses – Maricar Malinis

2:30 p.m. COVID-19: What We Know About Humoral and Cellular Responses? – Paolo Cravedi

3:00 p.m. Immune Responses in Transplant Recipients Who Received a Third Dose of mRNA-1273 – Atul Humar

3:30 p.m. Vaccine Effectiveness in Transplant Recipients – Andrew Karaba

Program is subject to change.
Friday, November 4, 2:00 p.m. – 4:00 p.m.

Molecular Diagnostics in Interpretation of Native and Transplant Kidney Biopsies

Support is provided by an educational grant from Travere Therapeutics, Inc.

Moderators: Enver Akalin, Ivy Rosales

2:00 p.m. Glomerular Transcriptomic Profiles in Nephrotic Syndrome – Jeffrey Hodgin
2:30 p.m. Transcriptomic Studies in IgA Nephropathy and Lupus Nephritis – Francesco Schena
3:00 p.m. Transcriptomics and the Pathogenesis of Diabetic Nephropathy – Raymond Harris
3:30 p.m. Molecular Diagnostics of Kidney Transplant Rejection: An Update – Candice Roufosse

Novel Strategies for Preventing End-Organ Damage and Dysfunction from CKD-MBD, Including the Jack W. Coburn Endowed Lectureship

ASN gratefully acknowledges Amgen for support of the Jack W. Coburn, MD, Endowed Lectureship.

Moderators: Valentin David, Jessica Kendrick

2:00 p.m. A Tangled Web: Complex Relationship Between CKD-MBD, Inflammation, and Anemia – Jodie Babitt
2:30 p.m. Contribution of Urinary Phosphate to CKD Progression – Kyle Jansson
3:00 p.m. Novel Strategies for the Prevention of Vascular Calcification in CKD – Demetrios Braddock
3:30 p.m. Systems Biology Approach to the Management of CKD-MBD: The Jack W. Coburn, MD, Endowed Lectureship – Eleanor Lederer

Friday, November 4, 4:30 p.m. – 6:00 p.m.

Where It Begins: Complex Genetic Drivers of Kidney Phenotypes

Moderators: Moumita Barua, Afshin Parsa

4:30 p.m. GWAS Identify Risk Variants in Diabetic Nephropathy – Jose Florez
4:50 p.m. GWAS-Defined Drug Targets in IgA Nephropathy – Krzysztof Kiryluk
5:10 p.m. Integrating Multiomics Data for a Better Understanding of Kidney Function and Disease – Anna Kottgen
5:30 p.m. APOL1: Toward Precision Medicine Approaches – Adriana Hung

AKI in Cirrhosis: Will Personalized Management Improve Outcomes?

Moderators: Jean Maxime Cote, Ashita Tolwani

4:30 p.m. Pathogenesis of Hepatorenal Syndrome – Juan Carlos Velez
4:50 p.m. Albumin Therapy in Cirrhosis: Too Much of a Good Thing? – Andrew Allegretti
5:10 p.m. Vasoconstrictor Therapy in Hepatorenal Syndrome: What Is the Evidence? – Mitra Nadim
5:30 p.m. AKI Biomarkers in Patients with Cirrhosis: Can Improved Phenotyping Guide Better Therapy? – Justin Belcher
Friday, November 4, 4:30 p.m. – 6:00 p.m.

**Leveraging Social Media to Create, Learn, Teach, Advocate, and Dispel Misinformation......W304**
Moderators: Bourne Auguste, Gates Colbert

- 4:30 p.m. Medical Illustrations and Visual Abstracts as a Means to Effectively Communicate Science – Sophia Ambruso
- 4:55 p.m. Podcasts for Medical Education: Learning by Listening – Adam Rodman
- 5:20 p.m. What Can a Nephrologist Do About Medical Misinformation? – Jen Gunter

**Trauma Behind My Smile: Better Access to Behavioral Health Resources During the Transplant Process, Including the Celeste Castillo Lee Endowed Lectureship..........WF3 Tangerine**
ASN gratefully acknowledges Travere Therapeutics and several of Celeste’s family members, friends, and colleagues for support of the Celeste Castillo Lee Endowed Lectureship.
Moderators: Anne Dawson, Martha Pavlakis

- 4:30 p.m. Incorporating Mental Health Practices by Increasing Psychosocial Education for Kidney Recipients: The Celeste Castillo Lee Endowed Lectureship – Patrick Gee
- 4:50 p.m. Impact of Having Access to Behavioral Health for Kidney Recipients – Nichole Jefferson
- 5:10 p.m. Behavioral Challenges That May Arise and Adherence Before and After Kidney Transplantation – Jennifer Jones
- 5:30 p.m. Goal-Directed Behavioral Health Tools and Lack of Access to Behavioral Health – Jennifer Steel

**Advancing Clinical Trials for People with Kidney Diseases: An Overview.............WF2 Tangerine**
Moderators: Lynee Galley, Amanda Grandinetti

- 4:30 p.m. Primer on Conducting Clinical Trials – Aliza Thompson
- 4:50 p.m. Patient Advisory Boards That Guide Design, Outreach, and Engagement for Your Clinical Trials – Glenda Roberts
- 5:10 p.m. Developing Studies to Engage Diverse Communities Where They Are – Opeyemi Olabisi
- 5:30 p.m. Conducting Clinical Trials for Innovative Therapeutics – Barbara Gillespie

**Building Capacity to Collect Patient Preferences Information for Innovative Kidney Devices...............................................................W315**
*Note: Continuing education credits are not being offered for this activity.*
Friday, November 4, 4:30 p.m. – 6:00 p.m.

Oral Abstract Sessions

Advances in Mineral Metabolism and Nephrolithiasis

Moderators: Rosa Moyses, Anna Zisman

4:30 p.m.  FR-OR01 The Effect of a Fermentable Dietary Fiber Inulin on a Rat Model of CKD-MBD – Neal Chen

4:39 p.m.  FR-OR02 Estrogen Protects Female Mice With CKD From Developing FGF23-Induced Left Ventricular Hypertrophy – Dominik Kentrup

4:48 p.m.  FR-OR03 Vitamin D Receptor Regulates Furin-Mediated FGF23 Cleavage – Petra Simic

4:57 p.m.  FR-OR04 Skeletal Muscle Is a Novel Source of FGF23 in Mouse Models of CKD and Skeletal Muscle Atrophy – Kylie Heitman

5:06 p.m.  FR-OR05 Parathyroectomy Decreases Muscle Expression of TGF-β1 and Improves Muscle Function – Eduardo Duque

5:15 p.m.  FR-OR06 Early Changes in Bone Turnover Markers Predict Bone Loss After Kidney Transplantation – Hanne Joergensen

5:24 p.m.  FR-OR07 Hepatocyte Nuclear Factor 4 Alpha 2 Is a Novel Osteoblast Transcription Factor That Plays a Role in CKD-MBD – Marta Martinez-Calle

5:33 p.m.  FR-OR08 Encaleret Normalized Mineral Homeostasis in Autosomal Dominant Hypocalcemia Type 1 (ADH1) in a Phase 2 Study – Kelly Roszko

5:42 p.m.  FR-OR09 A Spatially Anchored Transcriptomic Atlas of the Human Kidney Papilla Identifies Significant Immune Injury and Matrix Remodeling in Stone Disease Patients – Angela Sabo

5:51 p.m.  FR-OR10 Crystalluria Impairs Macrophage Function During Kidney Stone Formation – Tanecia Mitchell

AKI Research: Mechanisms

Moderators: Zheng Dong, Leah Siskind

4:30 p.m.  FR-OR11 Intracellular Magnesium Trafficking: A Novel Target to Prevent Ischemic Kidney Injury – William Reeves

4:39 p.m.  FR-OR12 Proximal Tubule Pannexin 1 Channel Regulates Cell Death and Inflammation During AKI – Nabin Poudel

4:48 p.m.  FR-OR13 Proteomic Analysis Reveals Proteins Associated Exclusively With Urinary Muddy Brown Granular Casts – Michael Janech

4:57 p.m.  FR-OR14 Ketone Body Metabolism in Renal Endothelium Triggers PPAR Signaling, Reduces Immune Cell Recruitment, and Preserves Kidney Function Upon Ischemia/Reperfusion Injury – Mila Borri

5:06 p.m.  FR-OR15 Kidney Injury Molecule-1 (KIM-1) Shapes the Kidney Immune Microenvironment via Lymphotxin Beta Receptor (LTβR) Signaling – Naoka Murakami

5:15 p.m.  FR-OR16 Kidney Resident Macrophages Alter MHC II Expression and Location in Response to Acute and Chronic Injury – Elise Erman

5:24 p.m.  FR-OR17 Tubular Epithelium-Specific Deletion of Megalin Aggravates Ischemia/Reperfusion Kidney Injury and Accelerates the Progression to CKD – Qingtian Li

5:33 p.m.  FR-OR18 The Role of the Circadian Clock System in the Transition From AKI to CKD – Yina Fang

5:42 p.m.  FR-OR19 TIGIT Modulates Kidney T Cell Memory Phenotype and Metabolic Profile and Mediates Both Ischemic and Nephrotoxic AKI in Mice – Sanjeev Noel

5:51 p.m.  FR-OR20 Proximal Tubular Epithelial Cell States in KPMP Protocol Kidney Biopsies Are Linked to Short-Term AKI Patient Outcomes – Jennifer Schaub
Friday, November 4, 4:30 p.m. – 6:00 p.m.

**CKD: Clinical Outcomes, Trials, Mechanistic Insights**

Moderators: Teresa Chen, James Wetmore

4:30 p.m.  
**FR-OR21** Air Pollution, Genetic Factors, and the Risk of Incident CKD: A Prospective Study of Polygenic Risk Score Analysis in the UK Biobank – Boram Weon

4:39 p.m.  
**FR-OR22** Time-Dependent Risk Differences in Kidney Failure and Death Between Black and White Veterans Following Incident CKD – Guofen Yan

4:48 p.m.  
**FR-OR23** Protein Carbamylation and the Risk of CKD Progression – Sahir Kalim

4:57 p.m.  
**FR-OR24** Changes in CKD Prevalence in the United States Using the Age-Adapted CKD Classification System – Maria Clarissa Tio

5:06 p.m.  
**FR-OR25** Dipstick Urinalysis Protein and Specific Gravity Can Identify Patients With Early CKD Who Lack a Quantified Proteinuria Measurement – Meredith McAdams

5:15 p.m.  
**FR-OR26** Dapagliflozin Effect on Hospital Admissions in Patients With CKD: A Post-Hoc Analysis of the DAPA-CKD Trial – Meir Schechter

5:24 p.m.  
**FR-OR27** Notch Blockade Specifically in FSP1-Positive Cells Ameliorates Renal Fibrosis by Attenuating Inflammation – Jizhong Cheng

5:33 p.m.  
**FR-OR28** Cyclin G1 Promotes Proximal Tubule Cell Maladaptive Dedifferentiation and Fibrosis in CKD – Bertha Elias

5:42 p.m.  
**FR-OR29** PRDM16 Protected Tubular Mitochondrial Function and Attenuated Renal Fibrosis by Upregulating PGC-1α – Qian Yuan

5:51 p.m.  
**FR-OR30** Unbiased Human and Mouse Kidney Metabolomics Identifies the Key Role of NAD Metabolism in Kidney Disease Development – Tomohito Doke

Diabetic Kidney Disease: From Single Cell to Outcomes

Moderators: John He, Karin Jandeleit-Dahm

4:30 p.m.  
**FR-OR31** The Single-Cell Landscape of Kidney Immune Cells Reveals Transcriptional Heterogeneity in Late Diabetic Kidney Disease – Jia Fu

4:39 p.m.  
**FR-OR32** Human Kidney Multimodal Single Cell and Spatial Transcriptomics Atlas Identify Key Cell Types and Pathways for Diabetic Kidney Disease – Amin Abedini

4:48 p.m.  
**FR-OR33** Multi-Omic Analysis Identifies a New Class of Proximal Tubular Cell With Metabolic Alterations in Diabetic Kidney Disease – Hiroshi Maekawa

4:57 p.m.  
**FR-OR34** Combination of Transcriptional Signatures and 3D Images of Epithelial Nuclei in Kidney Biopsies Using a Deep-Learning Outlier Detection Model Uncovers Signatures of Injury in Diabetic Kidney Disease – Seth Winfree

5:06 p.m.  
**FR-OR35** Identification of Early Diabetes-Induced Renal Changes Using Spatial Metabolomics – Rosalie Rietjens

5:15 p.m.  
**FR-OR36** Multi-Omics Integration Links Angiopoietin-Tie Signaling Pathway Activation With Diabetic Kidney Disease Progression – Viji Nair

5:24 p.m.  
**FR-OR37** A Prospective Study of Urinary Complement Proteins in Early Diabetic Kidney Disease in Type 1 Diabetes – Zaipul I Md Dom

5:33 p.m.  
**FR-OR38** Endogenous Retroviruses Contribute to Kidney Fibrosis Development by Triggering the Innate Immune Response – Poonam Dhillon

5:42 p.m.  
**FR-OR39** A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC) – Vlado Perkovic

5:51 p.m.  
**FR-OR40** Safety and Preliminary Efficacy Results of a Novel Mesenchymal Stromal Cell Therapy in Diabetic Kidney Disease: The Multicenter, Randomized, Placebo-Controlled, Phase-1b/2a NEPHSTROM Clinical Trial – Matthew Griffin

Program is subject to change.
Fluid, Electrolyte, and Acid-Base Disorders Research

Friday, November 4, 4:30 p.m. – 6:00 p.m.

Moderators: Robert Fenton, Evan Ray

4:30 p.m. FR-OR41 The Impact of Microgravity on Kidney Function During Spaceflight – Keith Siew

4:39 p.m. FR-OR42 Dietary Anion Controls Potassium Excretion: It’s More Than a Poorly Absorbable Anion Effect – Lama Al-Qusairi

4:48 p.m. FR-OR43 Wearable Device for Continuous, Non-Invasive Monitoring of Serum Potassium in Hemodialysis Patients – Forrest Miller

4:57 p.m. FR-OR44 KCC3a, a Pathway for Potassium Loss in Alkalaeia – Mohammed Ferdaus

5:06 p.m. FR-OR45 Complications and Treatment of Hypercalciuria in Familial Hyperkalaemic Hypertension (FHHt) – Viola D’Ambrosio

5:15 p.m. FR-OR46 Insulin Receptor Substrate 4 (IRS4) Contributes to Hypermagnesemia by Mediating the Insulin Effect on the Renal Magnesium Channel TRPM6 – Matthias Wolf

5:24 p.m. FR-OR47 Salt-Sensitive Blood Pressure Response in CKD Is Not Volume Mediated – Jetta Oppelaar

5:33 p.m. FR-OR48 In Vivo and In Vitro Effects of Hypoxia on NKCC2: Role of MAGE-D2 – Kamel Laghmani

5:42 p.m. FR-OR49 One Size Does Not Fit All: Real World Data on the Safety of Bolus Hypertonic Saline for Symptomatic Hyponatremia – Anissa Pelouto

5:51 p.m. FR-OR50 Thiazides Induce Glucose Intolerance Through Inhibition of Mitochondrial Carbonic Anhydrase 5b in β-Cells – Patrycja Kucharczyk

Glomerular Diseases: From Bench to Bedside

Moderators: Samir Parikh, Bethany Roehm

4:30 p.m. FR-OR51 The Predictive and Prognostic Value of Antigen-Specific Memory B Cell Levels in PLA2R-Associated Primary Membranous Nephropathy – Quansheng Zhu

4:39 p.m. FR-OR52 APOL1 Promotes Endothelial Cell Activation Beyond the Glomerulus – Miguel Carracedo

4:48 p.m. FR-OR53 Identification of Glomerular and Plasma APOM as Novel Biomarkers in Glomerular Disease – Yelena Drexler

4:57 p.m. FR-OR54 Urinary CD4+ T Cell Quantification Identifies ANCA Patients at Risk for Subsequent Renal Flares: Results of the Prospective, Multicenter Pre-Flared Study – Luka Prskalo

5:06 p.m. FR-OR55 Explainability of a Deep Learning Based Classification Model for ANCA-Associated Glomerulonephritis – Maria Wester Trejo

5:15 p.m. FR-OR56 Sparsentan Improves Glomerular Endothelial and Podocyte Functions and Augments Protective Tissue Repair in a Mouse Model of Focal Segmental Glomerulosclerosis (FGSS) – Georgina Gyarmati

5:24 p.m. FR-OR57 Long-Term Efficacy and Safety of Sparsentan in FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE) – Tarak Srivastava

5:33 p.m. FR-OR58 Efficacy and Safety of Voclosporin Over 3 Years in Patients With Severe Lupus Nephritis – Hanni Menn-Josephy

5:42 p.m. FR-OR59 Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy – Brad Rovin

5:51 p.m. FR-OR60 A Multi-Omics Approach to IgA Nephropathy Characterization in the NURTuRE Cohort Enables Precision-Based Treatment Approaches – N. Olson
<table>
<thead>
<tr>
<th>Poster Topics</th>
<th>Board #s</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIDDK and Informational Posters</td>
<td>INFO01–40</td>
</tr>
<tr>
<td>COVID-19: AKI Outcomes, Biomarkers, Treatments, Case Reports</td>
<td>001–059</td>
</tr>
<tr>
<td>AKI: Epidemiology, Risk Factors, Prevention</td>
<td>060–115</td>
</tr>
<tr>
<td>AKI: Mechanisms - II</td>
<td>116–175</td>
</tr>
<tr>
<td>Onconephrology: Clinical and Research Advances - I</td>
<td>176–215</td>
</tr>
<tr>
<td>Pharmacology</td>
<td>216–241</td>
</tr>
<tr>
<td>Genetic Diseases of the Kidneys: Cystic - II</td>
<td>242–301</td>
</tr>
<tr>
<td>Genetic Diseases: Models, Mechanisms, Treatments</td>
<td>302–348</td>
</tr>
<tr>
<td>Genetics, Development, Regeneration</td>
<td>349–407</td>
</tr>
<tr>
<td>Pediatric Nephrology - I</td>
<td>408–450</td>
</tr>
<tr>
<td>Peritoneal Dialysis: Current Topics</td>
<td>451–506</td>
</tr>
<tr>
<td>Home Dialysis, Policy, Novel Approaches</td>
<td>507–541</td>
</tr>
<tr>
<td>Fluid, Electrolyte, and Acid-Base Disorders: Clinical</td>
<td>542–574</td>
</tr>
<tr>
<td>Glomerular Diseases: Lupus and Vasculitis</td>
<td>575–633</td>
</tr>
<tr>
<td>Glomerular Diseases: Clinical, Outcomes, Trials - II</td>
<td>634–683</td>
</tr>
<tr>
<td>Glomerular Diseases: Podocyte Biology - I</td>
<td>684–734</td>
</tr>
<tr>
<td>Hypertension and CVD: Clinical, Outcomes, Trials</td>
<td>735–761</td>
</tr>
<tr>
<td>Transplantation: Clinical - Biomarkers</td>
<td>762–805</td>
</tr>
<tr>
<td>Transplantation: Clinical - Outcomes</td>
<td>806–858</td>
</tr>
<tr>
<td>Diversity and Equity in Kidney Health - II</td>
<td>859–898</td>
</tr>
<tr>
<td>CKD: Epidemiology, Risk Factors, Prevention - II</td>
<td>899–949</td>
</tr>
<tr>
<td>CKD: Pathobiology - I</td>
<td>950–1009</td>
</tr>
</tbody>
</table>

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.

---

**Wi-Fi Service**

Free internet access is available in the convention center throughout the meeting.

**Network**  
*kidneyweek*  

*No password needed*
ASN has simplified your educational experience. Access thousands of expert presentations, test your knowledge with self-assessment programs, and earn CE credits/MOC points, all from the ASN eLearning Center.

For more information on this streamlined professional resource, visit asn-online.org/elearning or scan the QR code. Questions? Email education@asn-online.org.
The latest in nephrology science and news.

Learn more at www.asnjournals.org or scan the QR code using your phone camera.
# DAY-AT-A-GLANCE

## Saturday, November 5

### 8:00 a.m. – 9:30 a.m.

**Plenary: KidneyCure Announcement, Robert G. Narins Award, Belding H. Scribner Award, Homer W. Smith Award and Address, State-of-the-Art Lecture**

- Location: W415 Valencia

### 9:30 a.m. – 2:30 p.m.

- **Morning Break**
  - Location: West Exhibit Hall D
- **Scientific Exposition and Posters**
  - Location: West Exhibit Hall D
- **Poster Presentations by Authors**
  - Location: West Exhibit Hall D

### 10:30 a.m. – 12:30 p.m.

**Basic/Clinical Science Sessions**

- **Nanodelivery in Organ Transplantation: Myth or Reality?**
  - Location: WF3 Tangerine
- **Pediatric Dialysis: Innovations, (Quality) Improvements, and Insights**
  - Location: W240
- **Role of Basolateral Potassium Channel in Potassium Homeostasis and Diseases**
  - Location: W230

**Clinical Practice Sessions**

- **Advancing Home Dialysis with Technologies and Education**
  - Location: WF2 Tangerine
- **Kidney and Fluid: A Love-Hate Relationship**
  - Location: W311
- **Renal Biopsy: Clinical Correlations 2022**
  - Location: W304
- **Value-Based Payment Models Generating New Approaches to Kidney Disease Care**
  - Location: WF1 Tangerine

**Translational Sessions**

- **Calciprotein Particles and Calcification Propensity in CKD-MBD**
  - Location: W414
- **Imaging the Diabetic Kidney**
  - Location: W224
- **The Yellow Brick Road? Rethinking Clinical Development Strategies in AKI**
  - Location: W320 Chapin

**Other Events**

- **Establishing Policy for Supportive Care in Kidney Health**
  - Location: W315
- **Innovate Kidney: KidneyX Innovators Showcase**
  - Location: West Exhibit Hall D

### 12:45 p.m. – 1:45 p.m.

**Educational Symposia (Hyatt Regency Orlando) – Doors open at 12:30 p.m.**

- **Emerging Therapies for ANCA-Associated Vasculitis**
  - Location: Regency Ballroom R
- **Hyperkalemia: Understanding and Applying Innovative Approaches to the Management of CKD and ESKD**
  - Location: Regency Ballroom S
- **Recognizing and Managing the Itch of CKD-Associated Pruritus: Scratching the Surface**
  - Location: Regency Ballroom T

### 2:00 p.m. – 4:00 p.m.

**Basic/Clinical Science Sessions**

- **Genetics and Clinical Implications of APOL1 Nephropathy**
  - Location: WF1 Tangerine
- **Immunity: Friend and Foe in People on Dialysis**
  - Location: W415 Valencia
- **Kidney and Genitourinary Development: Clinical Considerations for Pediatric Nephrologists**
  - Location: W240
- **Magnesium: The Forgotten Mineral**
  - Location: W414
- **Spatial Analysis of the Kidneys**
  - Location: W315
- **What’s the Time in the Tubule?**
  - Location: W230
2:00 p.m. – 4:00 p.m.

Clinical Practice Sessions
Antigens Underlying Glomerular Diseases: Diagnostic, Pathogenic, and Clinical Implications............... W314
Nephrology Quiz and Questionnaire 2022................................................................. W304
Optimizing the Delivery, Safety, and Outcomes of Kidney Replacement Therapy in People with AKI ................................................................. W307
Perspectives on Personalized Nutrition Care in Kidney Diseases and Implementation Challenges.............................................................. WF2 Tangerine
Reaching the Edge: Kidneys in Advanced Heart Failure ..................................................... W311
Recurrent Glomerulonephritis After Kidney Transplantation: Diagnostic and Therapeutic Approaches ................................................................. WF3 Tangerine
Should Disease Names Change to Reflect Genotype, Pathology, or Phenotype, and What Do Patients Think? ......................................................... W320 Chapin

Translational Sessions
Kidney Biopsies and Diabetic Kidney Disease........................................................................ W224
Thrifty Genes, Nephron Endowment, and Loss: AKI Lessons from Development,
Pediatrics, and Aging, Including the Barry M. Brenner, MD, Endowed Lectureship................ W308

4:00 p.m. – 4:30 p.m.

Afternoon Break...................................................... West Lobby D, West Lobby E/F, W415 Valencia Foyer, and W320 Foyer

4:30 p.m. – 6:00 p.m.

Basic/Clinical Science Sessions
Leveraging Data Science to Improve Kidney Health .......................................................... WF2 Tangerine
Metabolic Pathways and Diabetic Kidney Disease: Joint ASN-ADA Session........................ W224
See the World Through a Different Lens: Kidney Genomics Beyond Monogenic Disease................................. WF1 Tangerine

Clinical Practice Sessions
Best of NephJC.............................................................................................................. W304
The Many Faces of Drug-Induced Kidney Injury............................................................ WF3 Tangerine

Oral Abstract Sessions
COVID-19 and Kidney Diseases: Mechanisms and Management......................................... W230
Genetics, Development, and Therapies........................................................................... W308
Glomerular Diseases: Mechanisms of Cellular Injury...................................................... W414
High-Impact CKD Potpourri: Something for Everyone .................................................. W307
Transplantation: Clinical Outcomes and Biomarkers..................................................... W240

Other Event
Innovate Kidney: Challenges on Clinical Trials for Novel Kidney Drugs and
Meet-and-Greet with the Kidney Health Initiative Board ............................................. W315

Topical Chat
First-Year Attendings................................................................................................. W221A
Saturday, November 5, 8:00 a.m. – 9:30 a.m.

Plenary: KidneyCure Announcement, Robert G. Narins Award, Belding H. Scribner Award, Homer W. Smith Award and Address, State-of-the-Art Lecture

8:00 a.m. KidneyCure Announcement
8:10 a.m. Robert G. Narins Award – Mark Perazella
8:20 a.m. Belding H. Scribner Award – Phyllis August
8:30 a.m. Homer W. Smith Award and Address “Urea Transport to Nephrogenic Diabetes Insipidus: Using Physiology to Develop Novel Therapy” – Jeff Sands
9:00 a.m. State-of-the-Art Lecture “mRNA as Medicine” – Melissa Moore

Saturday, November 5, 10:30 a.m. – 12:30 p.m.

Nanodelivery in Organ Transplantation: Myth or Reality? WF3 Tangerine

Moderators: Daniel Heller, Martina McGrath

10:30 a.m. Lymphoid Targeted Immune Therapy in Transplantation – Reza Abdi
11:00 a.m. Stabilization of Cell-Cell Junctions: Novel Approach for Combating Ischemia Reperfusion Injury – Carl Atkinson
11:30 a.m. Nanoparticle-Based Targeted Drug Delivery to Prevent Ischemia Reperfusion Injury in Kidney Transplantation – Satish Nadig
12:00 p.m. Nanoparticle-Based Targeted Cellular Delivery in Transplantation – Xun-Rong Luo

Pediatric Dialysis: Innovations, (Quality) Improvements, and Insights W240

Moderators: Vimal Chadha, Vivian Shih

10:30 a.m. New Innovations in Pediatric Dialysis – Ayse Akcan Arikan
11:00 a.m. Dialysis as a CVD Risk Factor in Children: Mechanism and Management – Donald Weaver
11:30 a.m. Improvements in Dialysis Care Related to Quality Improvement Initiatives – Rebecca Ruebner
12:00 p.m. Children and Adolescents on Dialysis: Psychosocial Concerns and Caregiver Burden – Aaron Wightman, Taylor House

Role of Basolateral Potassium Channel in Potassium Homeostasis and Diseases W230

Moderators: Chou-Long Huang, Janet Klein

10:30 a.m. Physiological and Pathophysiological Roles of Kir5.1 (KCNJ16) in the Kidneys – Alexander Staruschenko
11:00 a.m. Kir4.1/Kir5.1 in the Distal Convoluted Tubule Regulates Potassium Homeostasis – WenHui Wang
11:30 a.m. WNKs are Potassium-Sensitive Kinases – Aylin Rodan
12:00 p.m. Next-Generation Inward Rectifier Potassium Channel Modulators: Discovery and Molecular Pharmacology – Jerod Denton
Saturday, November 5, 10:30 a.m. – 12:30 p.m.

Advancing Home Dialysis with Technologies and Education .............................................WF2 Tangerine
Moderators: Lisa Koester, Eric Weinhandl
10:30 a.m. Kidney Disease Education – Jane Davis
11:00 a.m. Can Transitional Dialysis Units Succeed? – Prayus Tailor
11:30 a.m. Advancing Technologies in Home Dialysis – Brent Miller
12:00 p.m. Transitioning of Modalities from Peritoneal Dialysis to Home Hemodialysis – Michael Kraus

Kidney and Fluid: A Love-Hate Relationship ..............................................................................W311
Moderators: Gabriel Contreras, Vandana Niyyar
10:30 a.m. Fluid Management in Critically Ill Patients: To Fill or Not to Fill – Amir Kazory
11:00 a.m. Assessment of Volume Status in Patients with ESKD: How Dry Is Dry? – Rajiv Agarwal
11:30 a.m. Congestive Nephropathy in Heart Failure: Underrecognized and Underappreciated – Eddie Greene
12:00 p.m. VExUS: Venous Excess Doppler Ultrasound for the Quantification and Monitoring of Venous Congestion – Abhilash Koratala

Renal Biopsy: Clinical Correlations 2022 ......................................................................................W304
ASN thanks the Renal Pathology Society for assistance with this session.
Moderators: Jean Hou, Kelly Smith
Clinical Discussant: Sean Barbour
10:30 a.m. Renal Pathology Case Study 1 – Vivek Charu
11:00 a.m. Renal Pathology Case Study 2 – Nicole Andeen
11:30 a.m. Renal Pathology Case Study 3 – Renate Kain
12:00 p.m. Renal Pathology Case Study 4 – Benjamin Adam

Value-Based Payment Models Generating New Approaches to Kidney Disease Care ..........................................................................................WF1 Tangerine
Moderators: Brendan Bowman, Eugene Lin
10:30 a.m. Push the Right Buttons for Better Kidney Disease Care: Value-Based Models – Daniel Weiner
11:00 a.m. Going It Alone: The Kidney Care First Option – Gaurav Jain
11:30 a.m. Together We Can Make It Happen: The Comprehensive Kidney Care Contracting Option – Dylan Steer
12:00 p.m. Let Us Bring Our Team to You: Wrap-Around Kidney Care Companies – Shaminder Gupta

Calciprotein Particles and Calcification Propensity in CKD-MBD..................................................W414
Moderators: Cecilia Giachelli, Anna Jovanovich
10:30 a.m. Overview of Calciprotein Composition, Isolation, and Quantification Techniques – Edward Smith
11:00 a.m. Mechanisms of Calciprotein Formation and Processing – Willi Jahnen-Dechent
11:30 a.m. Calciprotein Particles as Drivers of Inflammation and Cellular Damage – Elisabeth Jaeger
12:00 p.m. Utility of Calcification Propensity Assays for Predicting Vascular Calcification – Wei Chen

Program is subject to change.
**Saturday, November 5, 10:30 a.m. – 12:30 p.m.**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.</td>
<td>Imaging Oxygenation – Petter Bjornstad</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Imaging Fat Content in the Kidney Parenchyma and More with Multiparametric Kidney MRI – TBD</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Infrared Spectroscopic Imaging – Michael Walsh</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>The BEAt-DKD Imaging Experience – Steven Sourbron</td>
</tr>
</tbody>
</table>

**The Yellow Brick Road? Rethinking Clinical Development Strategies in AKI**

Moderators: Javier Neyra, Danielle Soranno

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 a.m.</td>
<td>What Makes for an Exciting Preclinical Data Packet for AKI or CKD? – Katalin Susztak</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Rethinking End Points in Early Phase AKI Studies – Sushrut Waikar</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>An Adaptive Trial Platform for AKI? Promises and Perils – Kathleen Liu</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Lessons for AKI Research from Pragmatic Trials – Miguel Vazquez</td>
</tr>
</tbody>
</table>

**Establishing Policy for Supportive Care in Kidney Health**

Note: Continuing education credits are not being offered for this activity.

**Innovate Kidney: KidneyX Innovators Showcase**

Note: Continuing education credits are not being offered for this activity.

---

**Saturday, November 5, 12:45 p.m. – 1:45 p.m.**

**Educational Symposia (Hyatt Regency Orlando)** – Doors open at 12:30 p.m.

**Lunch is provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants.**

**Emerging Therapies for ANCA-Associated Vasculitis**

Support is provided by an educational grant from ChemoCentryx, Inc.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 p.m.</td>
<td>Introduction – Ulf Panzer (Moderator)</td>
</tr>
<tr>
<td>12:55 p.m.</td>
<td>Pathogenesis and Diagnostic Approaches to ANCA Vasculitis – Ingeborg Bajema</td>
</tr>
<tr>
<td>1:15 p.m.</td>
<td>Updates on the Treatment of ANCA Vasculitis – Rachel Jones</td>
</tr>
<tr>
<td>1:35 p.m.</td>
<td>Questions and Answers</td>
</tr>
</tbody>
</table>

**Hyperkalemia: Understanding and Applying Innovative Approaches to the Management of CKD and ESKD**

Support is provided by an educational grant from AstraZeneca Pharmaceuticals.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 p.m.</td>
<td>Introduction: The Physiology of Hyperkalemia – Kim Zuber (Moderator)</td>
</tr>
<tr>
<td>12:55 p.m.</td>
<td>The Impact of Hyperkalemia in the Treatment of CKD – Mitchell Rosner</td>
</tr>
<tr>
<td>1:15 p.m.</td>
<td>Pharmacological and Nonpharmacological Approaches to the Management of Hyperkalemia – Biff Palmer</td>
</tr>
<tr>
<td>1:35 p.m.</td>
<td>Questions and Answers</td>
</tr>
</tbody>
</table>

**Recognizing and Managing the Itch of CKD-Associated Pruritus:**

**Scratching the Surface**

Support is provided by an educational grant from CSL Vifor.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 p.m.</td>
<td>Introduction – Denise Link (Moderator)</td>
</tr>
<tr>
<td>12:55 p.m.</td>
<td>Pathogenesis and Diagnosis of CKD-Associated Pruritus – Sara Combs</td>
</tr>
<tr>
<td>1:15 p.m.</td>
<td>Optimal Treatment and Management Strategies for CKD-Associated Pruritus – David Steele</td>
</tr>
<tr>
<td>1:35 p.m.</td>
<td>Questions and Answers</td>
</tr>
</tbody>
</table>
Saturday, November 5, 2:00 p.m. – 4:00 p.m.

Genetics and Clinical Implications of APOL1 Nephropathy ...............................................................................WF1 Tangerine
Moderators: Opeyemi Olabisi, John Sedor
2:00 p.m. Population Genetics of APOL1 and Its Clinical Spectrum – Rulan Parekh
2:30 p.m. APOL1 and Potential Implications for Kidney Transplantation – Barry Freedman
3:00 p.m. Biology of APOL1 Nephropathy – Martin Pollak
3:30 p.m. Therapeutic Development in APOL1 Nephropathy – Ogo Egbuna

Immunity: Friend and Foe in People on Dialysis ..............................................................................................................W415 Valencia
Moderators: Simon Davies, Jennifer Flythe
2:00 p.m. Adverse Consequences of Immune Dysregulation in Dialysis Patients – Talat Alp Ikizler
2:30 p.m. Responses to Vaccines and Viruses in Dialysis Patients – Rupert Beale
3:00 p.m. Infection Prevention and Control: Lessons from Children – Kristina Bryant
3:30 p.m. Innate Immunity in Dialysis Patients – Anne-Catherine Raby

Kidney and Genitourinary Development: Clinical Considerations for Pediatric Nephrologists ...................................................................................................................W240
Moderators: Susan Furth, Michelle Starr
2:00 p.m. Making Sense of a Moving Target: Kidney Function and Dysfunction During Periods of Rapid Growth – Marissa Defreitas
2:30 p.m. Little Kidneys, Big Problems: Prematurity and Small Kidney Size as Risk Factors for CKD – Jennifer Charlton
3:00 p.m. Running on Empty: Barriers to Urinary Drainage and Associated Clinical Implications – Brian Becknell
3:30 p.m. Medical Conditions and Interventions That Impact Kidney Development: Pregnancy and Beyond – Keia Sanderson

Magnesium: The Forgotten Mineral .................................................................................................................................W414
Moderators: Diana Jalal, Cesar Romero
2:00 p.m. Role of the Kidneys in Magnesium Homeostasis – Joost Hoenderop
2:30 p.m. Genetic and Clinical Factors Associated with Magnesium Levels in the Population – John Lieske
3:00 p.m. Magnesium and the Molecular Mechanisms Driving Vascular Calcification – Jeroen De Baaij
3:30 p.m. Clinical Evidence for a Role of Magnesium Deficiency in CVD – Mirela Dobre

Spatial Analysis of the Kidneys ..........................................................................................................................................W315
Moderators: Daria Barwinska, Zoltan Laszik
2:00 p.m. Spatial Transcriptomics of the Kidneys – Laura Perin
2:30 p.m. Spatial Metabolomics in Human Kidneys – Kumar Sharma
3:00 p.m. Spatial Analysis of Immune Cells in the Kidneys – Marcus Clark
3:30 p.m. Imaging Mass Cytometry of the Human Kidneys – Lloyd Cantley

Program is subject to change.
Saturday, November 5, 2:00 p.m. – 4:00 p.m.

**What’s the Time in the Tubule?** ................................................................. W230
Moderators: Nirupama Ramkumar, Tianxin Yang
2:00 p.m.  **Circadian Regulation of Kidney Sodium Handling: Systemic Clock** – David Pollock
2:30 p.m.  **Circadian Regulation of Kidney Sodium Handling: Tubular Clock** – Lauren Douma
3:00 p.m.  **Tubular Clock Regulates Kidney Glucose Handling** – Xiaoyue Pan
3:30 p.m.  **Environmental Circadian Disruption and Kidney Function Rhythm and Injury** – Alec Davidson

**Antigens Underlying Glomerular Diseases: Diagnostic, Pathogenic, and Clinical Implications** .................................................. W314
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Tiffany Caza, Shikha Wadhwani
2:00 p.m.  **New Antigens in Membranous Nephropathy: Unique Clinicopathologic Features** – Sanjeev Sethi
2:30 p.m.  **New Antigens in Membranous Nephropathy: Potential Importance in Prognosis and Treatment** – Elion Hoxha
3:00 p.m.  **Recent Insights into the Pathogenesis of ANCA Glomerulonephritis and Vasculitis** – Duvuru Geetha
3:30 p.m.  **Infectious Antigens and Glomerulonephritis: An Update** – Samih Nasr

**Nephrology Quiz and Questionnaire 2022** .................................................. W304
Moderators: Melanie Hoenig, Michael Ross
2:00 p.m.  **Electrolyte and Acid-Base Disturbances** – Roger Rodby
2:30 p.m.  **Glomerular Diseases** – Pietro Canetta
3:00 p.m.  **Transplantation** – Beatrice Concepcion
3:30 p.m.  **Renal Replacement Therapy** – Nisha Bansal

**Optimizing the Delivery, Safety, and Outcomes of Kidney Replacement Therapy in People with AKI** .................................................. W307
Moderators: Rasheed Balogun, Luis Juncos
2:00 p.m.  **Evidence and Gaps Underpinning Current RRT Practice in the Intensive Care Unit** – Ashita Tolwani
2:30 p.m.  **“First, Do No Harm”: Iatrogenic Complications of Acute Kidney Replacement Therapy** – Anitha Vijayan
3:00 p.m.  **Using Data to Drive Improvement in the Clinical Outcomes of Kidney Replacement Therapy in AKI** – Javier Neyra
3:30 p.m.  **Leading the Charge: Organizational Considerations in AKI Survivor Care** – Stuart Goldstein
Perspectives on Personalized Nutrition Care in Kidney Diseases and Implementation Challenges ...........................................................................................................WF2 Tangerine
Moderators: Casey Rebholz, Jaime Uribarri
2:00 p.m.  Plant-Based Diets to Control CKD Progression in Adults and Children – Connie Rhee
2:30 p.m.  Personalized Nutrition Care: What Is It and How Can It Be Implemented? – Carla Avesani
3:00 p.m.  Assessing Global Kidney Nutrition Care: A Collaborative Initiative from the International Society of Renal Nutrition and Metabolism and International Society of Nephrology Global Kidney Health Atlas – Angela Yee Moon Wang
3:30 p.m.  Living with a Kidney Diet: A Patient’s Perspective – Dawn Edwards

Reaching the Edge: Kidneys in Advanced Heart Failure.................................................................................................................................W311
Moderators: Kianoush Kashani, Amir Kazory
2:00 p.m.  The Art of Volume Management in Heart Failure: From Assessment to Therapy – W.H. Wilson Tang
2:30 p.m.  Focus on POCUS: Can Point-of-Care Ultrasound Change Our Approach in Cardiorenal Syndrome? – Abhilash Koratala
3:00 p.m.  Love-Hate Relationship Between Kidney and Mechanical Circulatory Support Devices – Jeffrey Turner
3:30 p.m.  Inferior Vena Cava Ultrasound: Pearls and Pitfalls – Elaine Kaptein

Recurrent Glomerulonephritis After Kidney Transplantation: Diagnostic and Therapeutic Approaches ........................................................................WF3 Tangerine
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Nicolae Leca, Deirdre Sawinski
2:00 p.m.  Recurrence of FSGS After Kidney Transplantation – Leonardo Riella
2:30 p.m.  Recurrent Primary FSGS: Insights into the Pathogenesis of FSGS – Lorenzo Gallon
3:00 p.m.  APOL1 in Kidney Transplantation – Mona Doshi
3:30 p.m.  Recurrent Membranous Nephropathy: Diagnostic and Therapeutic Approach – Fernando Fervenza

Should Disease Names Change to Reflect Genotype, Pathology, or Phenotype, and What Do Patients Think? ...............................................................W320 Chapin
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Rasheed Gbadegesin, Catherine Quinlan
2:00 p.m.  Defining the Molecular Basis of Glomerular Disease – Matthias Kretzler
2:30 p.m.  Change the Name: Genetics-Focused Naming – Alicia Byrne
3:00 p.m.  Retain the Name: Pathology-Focused Naming – Astrid Weins
3:30 p.m.  Patient Perspective: Implications of Naming for Alport Syndrome – Susie Gear

Kidney Biopsies and Diabetic Kidney Disease...............................................................................................................................W224
Moderators: Eoin Brennan, Parker Wilson
2:00 p.m.  Historical Learnings on Kidney Pathology in Diabetes – Paola Fioretto
2:30 p.m.  Biopsy Findings in the Pima Population – Behzad Najafian
3:00 p.m.  Kidney Biopsies and Molecular Assessment of Kidney Disease – Andrew Malone
3:30 p.m.  Digital Pathology for Diabetic Kidney Disease – Vijaya Kolachalama

Program is subject to change.
Saturday, November 5, 2:00 p.m. – 4:00 p.m.

Thrifty Genes, Nephron Endowment, and Loss: AKI Lessons from Development, Pediatrics, and Aging, Including the Barry M. Brenner, MD, Endowed Lectureship .......... W308
ASN gratefully acknowledges Monarch Pharmaceuticals for support of the Barry M. Brenner, MD, Endowed Lectureship.

Moderators: Amanda Clark, Prasad Devarajan
2:00 p.m.  Developmentally Programming a Healthy Kidney: The Barry M. Brenner, MD, Endowed Lectureship – Andrew McMahon
2:30 p.m.  Applying Organoids to Interrogate AKI Mechanisms – Kyle McCracken
3:00 p.m.  How Children and Adults Differ in Terms of AKI Susceptibility and Outcomes – Shina Menon
3:30 p.m.  Influence of Aging Mechanisms on AKI Risk – Karl Nath

Saturday, November 5, 4:30 p.m. – 6:00 p.m.

Leveraging Data Science to Improve Kidney Health ................................................... WF2 Tangerine
ASN thanks the ASN AKINow Workgroup for assistance with this session.

Moderators: Sherry Mansour, Motoko Yanagita
4:30 p.m.  What Is the Full Potential of Electronic Medical Record Data in Relation to AKI? – Girish Nadkarni
4:50 p.m.  Let’s Talk Sequencing: What We Know and What the Future Holds – Parker Wilson
5:10 p.m.  Multi-Omics and Multi-Advancements in Kidney Health – Morgan Grams
5:30 p.m.  Learning About Machine Learning: How Effective Is It in Relation to AKI? – Ashish Verma

Metabolic Pathways and Diabetic Kidney Disease: Joint ASN-ADA Session ...................... W224
ASN thanks the American Diabetes Association for assistance with this session.

Moderators: Josephine Forbes, Padmanabhan Subramanian
4:30 p.m.  Dietary Factors – Matthew Snelson
4:50 p.m.  Autophagy – Reiko Inagi
5:10 p.m.  Sphingolipids – Sandra Merscher
5:30 p.m.  Mitochondria – Krisztian Stadler

See the World Through a Different Lens: Kidney Genomics Beyond
Monogenic Disease .......................................................................................................... WF1 Tangerine

Moderators: Rafael Kramann, Matt Sampson
4:30 p.m.  AKI Genotype, Susceptibility, and the Potential for Personalized Medicine – Emily See
4:55 p.m.  X-Linked Kidney Diseases in XX Patients – Michelle Rheault
5:20 p.m.  Barriers and Facilitators to the Implementation of Discovery Genomics in Routine Health Care – Daniel Gale

Best of NephJC .................................................................................................................. W304
ASN thanks NephJC for assistance with this session.

Moderators: Swapnil Hiremath, Caitlyn Vlasschaert
4:30 p.m.  Best of Hypertension Literature – Jade Teakell
4:50 p.m.  Best of Dialysis Literature – Graham Abra
5:10 p.m.  Best of AKI Literature – Francis Wilson
5:30 p.m.  Best of Basic Science Literature for the Clinician – Kelly Hyndman

54
Saturday, November 5, 4:30 p.m. – 6:00 p.m.

The Many Faces of Drug-Induced Kidney Injury .......................................................... WF3 Tangerine
Moderators: Melanie Joy, Namrata Krishnan
4:30 p.m.  
Acute Tubular Injury Associated with Medications: A Focus on Mitochondrial Toxicity  
– Mohamed Atta
4:50 p.m.  
Crystalline-Induced AKI from Medications: It’s More Than Tubular Obstruction  
– Felix Knauf
5:10 p.m.  
Vancomycin-Associated AKI, Three of a Kind: Acute Tubular Injury, Acute Interstitial Nephritis, and Cast Nephropathy  
– Erin Barreto
5:30 p.m.  
Drug-Induced Acute Interstitial Nephritis: The Great Masquerader  
– Maria Prendecki

Innovate Kidney: Challenges on Clinical Trials for Novel Kidney Drugs and Meet-and-Greet the Kidney Health Initiative Board  
............................................................................ W315
Note: Continuing education credits are not being offered for this activity.

Oral Abstract Sessions

COVID-19 and Kidney Diseases: Mechanisms and Management ............................................ W230
Moderators: Meghan Sise, Jacob Stevens
4:30 p.m.  
SA-OR01 Long-Term Renal Outcomes of COVID-19-Associated Nephropathy  
(COVAN)  
– Gabriel Giannini
4:39 p.m.  
SA-OR02 Renal Pathology of Fatal Cases of COVID-19: A Study of 94 Autopsies  
– Arian Pourmehdi Lahiji
4:48 p.m.  
SA-OR03 Incidence and Clinical Course of Gross Hematuria Following COVID-19 Vaccination Among Patients With IgA Nephropathy  
– Hitomi Kimura
4:57 p.m.  
SA-OR04 Urinary Transcriptomics Identified Inflammatory Signals Associated With COVID-19-Related AKI  
– Sean Eddy
5:06 p.m.  
SA-OR05 Single Nucleus RNA-Sequencing in Diagnostic Biopsy Cores of COVID-AKI Patients Reveals Robust Modelling, Injury, and Profibrotic Markers  
– Reetika Ghag
5:15 p.m.  
SA-OR06 Kidney Disease and COVID-19 Outcomes in the Temporal Analysis of Pandemic Waves  
– Ning Shang
5:24 p.m.  
SA-OR07 COVID-19 Pandemic Effect on Mortality of Hemodialysis Patients  
– Yan Zhang
5:33 p.m.  
SA-OR08 Vaccine Effectiveness of One, Two, or Three Doses of SARS-CoV-2 mRNA Vaccines in Maintenance Dialysis Patients  
– Harold Manley
5:42 p.m.  
SA-OR09 Clinical Efficacy of the Fourth Dose of the BNT162b2 Vaccine in Chronic Dialysis Patients  
– Moshe Shashar
5:51 p.m.  
SA-OR10 BOOST KIDNEY: A Randomized Controlled Trial of Third Dose BNT162b2 vs. mRNA-1273 COVID-19 Vaccination in CKD and Dialysis Patients  
– Kevin Yau

Program is subject to change.
Genetics, Development, and Therapies

Saturday, November 5, 4:30 p.m. – 6:00 p.m.

W308

Moderators: Satu Kuure, Kameswaran Surendran

4:30 p.m.  SA-OR11 Genome-Wide Association Studies of a Composite Renal Phenotype Reveal Pleiotropic Effects and a Novel Locus – Moumita Barua

4:39 p.m.  SA-OR12 Gene Surgery: A Potential CRISPR/Cas-Based Treatment Option for Nephropathic Cystinosis In Vitro – Elena Sendino Garvi

4:48 p.m.  SA-OR13 Channel Function of Polycystin-2 in Endoplasmic Reticulum Protects Against Polycystic Kidney Disease – Biswajit Padhy

4:57 p.m.  SA-OR14 Downregulation of O-GlcNAc Reduces Ciliary Length and Attenuates Renal Cystic Disease in PKD Mice – Matthew Kavanaugh

5:06 p.m.  SA-OR15 The Methionine-Mettl3-RNA Methylation Axis Is Essential for Nephrogenesis – Harini Ramalingam

5:15 p.m.  SA-OR16 Estrogen Signaling Is an Essential Regulator of Nephron Segmentation – Hannah Wesselman

5:24 p.m.  SA-OR17 Interstitial Notch Signaling Is Required for the Development of Proximal Tubules – Joo-Seop Park

5:33 p.m.  SA-OR18 ASH2L Is Essential for the Ureteric Bud Lineage Development – Ziyi Zhao

5:42 p.m.  SA-OR19 Establishing the Spatiotemporal Organization and Function of Renal Nerves Throughout Nephrogenesis – Pierre-Emmanuel N’Guetta

5:51 p.m.  SA-OR20 Deciphering the Origins of Kidney Lymphatics – Daniyal Jafree

Glomerular Diseases: Mechanisms of Cellular Injury

W414

Moderators: Christian Faul, Jyothsna Gattineni

4:30 p.m.  SA-OR21 Tenascin-C Promotes Migration and Proliferation of Parietal Epithelial Cells and Participates in the Pathogenesis of FSGS – Ke Sun

4:39 p.m.  SA-OR22 Cell-Specific Role of STAT3 Signaling in Podocytes vs. Parietal Epithelial Cells in Proliferative Glomerulopathy – Yogesh Gowthaman

4:48 p.m.  SA-OR23 Continuous Non-Mutagenic DNA Damage in Podocytes Activates Pathogenic Memory T Cells Through Altered DNA Methylation – Ran Nakamichi

4:57 p.m.  SA-OR24 γ Isoform of Phosphoinositide 3 Kinase Plays a Critical Role in Propagation of Podocyte Injury in a Genetic Podocytopathy – Xiaoyan Liang

5:06 p.m.  SA-OR25 A Possible Role of Anti-Nephrin Autoantibody in Endocytosis of Nephrin in Patients With Post-Transplant Focal Segmental Glomerulosclerosis Recurrence and Minimal Change Disease – Yoko Shirai

5:15 p.m.  SA-OR26 Podocyte-Specific Loss of Klf4 Induces the Formation of Extracellular Matrix Extensions – Nina Cintron Pregosin

5:24 p.m.  SA-OR27 RCAN1 I162T Variant Disrupts Calcineurin Regulation and Reduces Viability in Patient-Derived Podocytes – Kinzie Huggins

5:33 p.m.  SA-OR28 C3a/C3aR1 Signaling as a Crucial Pathogenic Mechanism in Membranous Nephropathy – Stefano Da Sacco

5:42 p.m.  SA-OR29 Targeting the Integrated Stress Response Pathway in T Cells Ameliorates Crescentic Glomerulonephritis in Mice – Nariaki Asada
Saturday, November 5, 4:30 p.m. – 6:00 p.m.

High-Impact CKD Potpourri: Something for Everyone ........................................................................................................... W307
Moderators: Nayan Arora, Tanjala Purnell

4:30 p.m.          SA-OR31 Linked by Love: Relatability and Cultural Appropriateness of an Edutainment Series About CKD in an African American Family – LaShara Davis

4:39 p.m.          SA-OR32 A Randomized Controlled Pilot Study of a Patient Decision Aid About Conservative Kidney Management – Susan Wong

4:48 p.m.          SA-OR33 Impact of Race/Ethnicity and Age on Hospitalization Outcomes in Advanced CKD Patients Treated With Conservative Management vs. Dialysis – Connie Rhee

5:06 p.m.          SA-OR35 Comparison of Clinical Outcomes Between Twice- vs. Thrice-Weekly Hemodialysis in Thai Elderly Patients: A Single-Center Study – Prapa Pattrapornpisut

5:15 p.m.          SA-OR36 Effects of Dapagliflozin on Anemia in Patients With CKD With or Without Type 2 Diabetes: A Pre-Specified Analysis of the DAPA-CKD Trial – Hiddo Heerspink

5:24 p.m.          SA-OR37 Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of Major Adverse Cardiovascular Events in the ASCEND Trials – Gregorio Obrador

5:33 p.m.          SA-OR38 Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Trials – Tom Greene

5:42 p.m.          SA-OR39 Effect of a Nutritional Supplement of Probiotics and/or Prebiotics vs. Placebo on Nutritional Status in Automated Peritoneal Dialysis (APD) Patients – Fabiola Martin del Campo

5:51 p.m.          SA-OR40 Obesity Weight Loss Phenotypes in CKD: Data From the Chronic Renal Insufficiency Cohort Study (CRIC) – Meera Harhay

Program is subject to change.

Transplantation: Clinical Outcomes and Biomarkers.............................................................................................................. W240
Moderators: Luz Liriano-Ward, Alexander Wiseman

4:30 p.m.          SA-OR41 Utilization of SARS-CoV-2 (COVID-19)-Positive Donor Kidneys – Warren McKinney

4:39 p.m.          SA-OR42 Viro-Immunological Monitoring as a Predictor for Complicative Events in the First Year After Kidney Transplantation: The VIRENO Study – Patrick Affeldt

4:48 p.m.          SA-OR43 A Randomized Phase 2 Study of MAU868 vs. Placebo to Treat BK Viremia in Kidney Transplant Recipients – Stanley Jordan

5:06 p.m.          SA-OR45 Acute Tubular Injury and Necrosis Do Not Lead to Meaningful Elevations in Donor-Derived Cell-Free DNA (dd-cfDNA) – Sridhar Reddy Allam

5:15 p.m.          SA-OR46 Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection – Rania El Fekih

5:24 p.m.          SA-OR47 Five-Year Follow-Up of a Phase 1 Trial of Donor-Derived Modified Immune Cell Infusion in Kidney Transplantation – Matthias Schaier

5:33 p.m.          SA-OR48 A Regimen of Nonmyeloablative Conditioning and CD8+/TCR- Facilitating Cells Tips the Balance Towards Immune Downregulation and Away From Cytopathic Activity in Kidney Allograft Recipients – John Lee

5:42 p.m.          SA-OR49 Clinical Performance Validation of Tuteva Biomarker – Oriol Bestard

5:51 p.m.          SA-OR50 Immune Cell Transcriptome in Living-Donor Kidney Transplant Patients Tolerized With Allogeneic Hematopoietic Stem Cell Transplantation Therapy – Jennifer McDaniel
### Poster Topics

<table>
<thead>
<tr>
<th>Board #s</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>INFO01–40</td>
<td>NIH/NIDDK and Informational Posters</td>
</tr>
<tr>
<td>001–031</td>
<td>Bioengineering</td>
</tr>
<tr>
<td>032–062</td>
<td>AKI: Important, Yet Underappreciated Causes</td>
</tr>
<tr>
<td>063–112</td>
<td>AKI: Mechanisms - III</td>
</tr>
<tr>
<td>113–160</td>
<td>Onconephrology: Clinical and Research Advances - II</td>
</tr>
<tr>
<td>161–219</td>
<td>Vascular Calcification, Nephrolithiasis, Bone</td>
</tr>
<tr>
<td>220–256</td>
<td>Diabetic Kidney Disease: Basic - II</td>
</tr>
<tr>
<td>257–284</td>
<td>Diabetic Kidney Disease: Clinical - II</td>
</tr>
<tr>
<td>285–344</td>
<td>Hemodialysis and Frequent Dialysis: Potpourri</td>
</tr>
<tr>
<td>345–404</td>
<td>Hemodialysis and Frequent Dialysis: CV and Risk Prediction</td>
</tr>
<tr>
<td>405–464</td>
<td>Hemodialysis and Frequent Dialysis: Clearance, Technology, Infection</td>
</tr>
<tr>
<td>465–521</td>
<td>Fluid, Electrolyte, and Acid-Base Disorders: Case Reports</td>
</tr>
<tr>
<td>522–583</td>
<td>Genetic Diseases: Diagnosis</td>
</tr>
<tr>
<td>584–628</td>
<td>Pediatric Nephrology - II</td>
</tr>
<tr>
<td>629–677</td>
<td>Glomerular Diseases: IgA and Complement-Mediated GN</td>
</tr>
<tr>
<td>678–730</td>
<td>Glomerular Diseases: Clinical, Outcomes, Trials - III</td>
</tr>
<tr>
<td>731–752</td>
<td>Glomerular Diseases: Podocyte Biology - II</td>
</tr>
<tr>
<td>753–793</td>
<td>Hypertension and CVD: Mechanisms</td>
</tr>
<tr>
<td>794–839</td>
<td>Transplantation: Clinical - Pretransplant Assessment and Living Donors</td>
</tr>
<tr>
<td>840–884</td>
<td>Transplantation: Clinical - Case Reports</td>
</tr>
<tr>
<td>885–919</td>
<td>CKD: Clinical Trials and Pharmacoepidemiology</td>
</tr>
<tr>
<td>920–954</td>
<td>CKD: Observational Research and Patient-Oriented Interventions</td>
</tr>
<tr>
<td>955–1013</td>
<td>CKD: Pathobiology - II</td>
</tr>
</tbody>
</table>

Abstract details are available in the Kidney Week app and at www.asn-online.org/kidneyweek.

### Kidney Week Virtual Platform

All meeting content will be available on the virtual meeting platform for in-person and virtual participants through Wednesday, December 21, 2022.

Log in at [www.asn-online.org/kwplatform](http://www.asn-online.org/kwplatform).

Scan the above QR code to log in.
Scientific Exposition

A vital part of the Kidney Week educational experience is found on the scientific exposition floor, West Exhibit Hall D, of the Orange County Convention Center. This unparalleled international venue provides demonstrations of products and services that will enhance your understanding of the latest advancements in pharmaceuticals, devices, imaging, and services important to high-quality patient care. On the exposition hall floor, you can engage in peer-to-peer interactions with representatives and businesses that form an integral part of your day-to-day fight against kidney disease and view thousands of accepted poster abstracts.

ASN is a member of the Healthcare Convention and Exhibitors Association (HCEA).

Exhibit Hall & Posters Hours

- **Thursday Nov. 3**
  - 9:30 a.m. – 2:30 p.m.

- **Friday Nov. 4**
  - 9:30 a.m. – 2:30 p.m.

- **Saturday Nov. 5**
  - 9:30 a.m. – 2:30 p.m.

**The Welcome Reception is supported by Fresenius Medical Care Renal Pharmaceuticals.**

**Scientific Exposition Refreshment Breaks are supported by ANI Pharmaceuticals, Inc.**

**Attendee Lounges are supported by GSK.**
Exhibitor Spotlight Schedule

Join your colleagues for the latest advances in nephrology practices, products, services, and technologies presented in two theaters on the exhibit hall floor (no continuing education credit). Seating is limited and available on a first-come, first-served basis.

All presentations include breakfast or lunch.

Thursday, November 3

10-10:45 a.m.
Jardiance® (empagliflozin) tablets: EMPEROR Clinical Trials Data Subgroup Analyses

Presented by Boehringer Ingelheim | Lilly

12:30-1:15 p.m.
Are You Thinking Genetic? The Emerging Role of Genetics in CKD

Presented by natera

Friday, November 4

10-10:45 a.m.
Understanding the Complexity of Patients with CKD: Implications for Management

Presented by AstraZeneca

12:30-1:15 p.m.
Developing Precision Medicines for Patients with IgAN

Presented by Chinook Therapeutics

Saturday, November 5

10-10:45 a.m.
Physician-Patient Discussion: Does Patient Care Need to Evolve for Anemia of CKD?

Presented by GSK Medical Affairs

12:30-1:15 p.m.
The Phosphorus Management Puzzle and Need for New Pieces: The Patient and Physician Perspective

Presented by Ardelyx
Thursday, November 3
11:30 a.m.-12:15 p.m.
The Cardiorenal Connection: Providing Dual Cardiorenal Risk Reduction for Patients with CKD Associated with T2D
Presented by Bayer

1-1:45 p.m.
Perspectives on OmniGraf Use in Clinical Practice
Presented by Eurofins

Friday, November 4
11:30 a.m.-12:15 p.m.
New Data on an Autosomal Dominant Polycystic Kidney Disease (ADPKD) Treatment Option
Presented by Otsuka
Otsuka America Pharmaceutical, Inc.

1-1:45 p.m.
The Importance of Achieving a Complete Response in Lupus Nephritis
Presented by Aurinia

Saturday, November 5
11:30 a.m.-12:15 p.m.
Surveillance Tools and Molecular Innovation for Transplant Patients
Presented by CareDx

1-1:45 p.m.
First Steps for Females with GLA Variants Detected by Kidney Disease Panels: Actionable Findings
Presented by sanofi

These events are not CE (continuing education) activities.
EXCELLENCE IN
Patient Care

Excellence in Patient Care (EPC) focuses on ASN's clinical priorities to provide high-quality care for people with kidney diseases. Key contributors include patient advocates, members of the kidney care team, and partners across the kidney community.

KIDNEY WEEK EVENTS

<table>
<thead>
<tr>
<th>COVID-19</th>
<th>DKD</th>
<th>AKINow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 11/3 2:00 – 4:00 p.m.</td>
<td>Thursday, 11/3 10:30 a.m. – 12:30 p.m.</td>
<td>Saturday, 11/5 4:30 – 6:00 p.m.</td>
</tr>
<tr>
<td>A Look in the Crystal Ball: COVID-19 and the Future of Outpatient Dialysis</td>
<td>The Patient Journey with Diabetic Kidney Disease</td>
<td>Leveraging Data Science to Improve Kidney Health</td>
</tr>
</tbody>
</table>

EPC PROJECTS AND INITIATIVES

• **Nephrologists Transforming Dialysis Safety (NTDS)** promotes transformational change that continuously improves the safety of dialysis

• **Quality Assessment, Improvement, & Education (QAIE)** creates and distributes infection prevention resources and best practices

• **Current and Emerging Threats (CET)** provides education and resources in the area of current and emerging bacterial, viral, and fungal threats

• **Human Factors Engineering** identifies facilitators and barriers to increased patient and staff safety through the study of human factors - “work as imagined versus work as performed”

• **Transforming Dialysis Access Together (TDAT)** pursues dialysis access justice, equity, diversity, and inclusion in medical training and patient care

• **Diabetic Kidney Disease Collaborative (DKD-C)** works together to address the urgent and unmet needs in the diagnosis and treatment of people with DKD

• **COVID-19 response** develops and disseminates resources to the kidney community during the current pandemic, and preparing for future crises

• **AKINow** promotes excellence in the prevention and treatment of acute kidney injury (AKI)

• **Adult Immunization Project (AIP)** advocates for the adoption of CDC’s Standards of Adult Immunization Practices in kidney care

• **Home Dialysis Project (HDP)** fosters awareness of and improved outcomes for home dialysis therapies and addressing disparities in access to home dialysis

Visit www.epc.asn-online.org for more information.
Follow us on Twitter AsnEpc
The ASN Research Discovery and Innovation department integrates three programs to stimulate, accelerate, and support biomedical research and innovations for people with kidney diseases.

- **KidneyCure** encourages and supports the kidney research and education workforce through grants and fellowships to pre-doctoral through early-career researchers.

- **Kidney Health Initiative** promotes the development of innovative treatment options for people with kidney diseases through a partnership between ASN, the US Food and Drug Administration, and over 100 member organizations.

- **KidneyX** is a partnership between ASN and the US Department of Health and Human Services that enables the development of breakthrough treatments in kidney care.

Visit www.asn-online.org to learn more about ASN’s work to increase the nephrology workforce pipeline and foster innovation in kidney care.
# DAY-AT-A-GLANCE

**Sunday, November 6**

## DAY-AT-A-GLANCE: Sunday, November 6

### 8:00 a.m. – 9:00 a.m.

**Plenary: Midcareer Awards, State-of-the-Art Lecture**
- ASN Business Meeting

### 9:30 a.m. – 11:30 a.m.

#### Basic/Clinical Science Sessions

- AKI: Old and New Players
- Nephron Progenitor Fate Determination and Maintenance

#### Clinical Practice Sessions

- Contemporary Management of Diabetic Kidney Disease:
  - Update on Recent Clinical Trials
- Ethical Challenges in Nephrology, Including the Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy
- Glomerular Diseases and Cancer: Cause or Effect?
- Pending Challenges When Addressing Donor Kidney Function:
  - How Low Is Low Before and After Donation

#### Translational Session

- Molecular Mechanisms of Hypertension and Cardiovascular Effects

---

## Kidney Week On-Demand

Never miss a session with Kidney Week On-Demand 2022. With over 200 hours of recorded Annual Meeting presentations, Kidney Week On-Demand is the best way to get the most out of your Annual Meeting experience. To get your complimentary access code, exchange this voucher at the following booth:

**Booth 1901**

All recorded presentations will be available in January 2023 on the ASN eLearning Center for up to three years.

Access codes are available during Exhibit Hall hours to fully paid Annual Meeting participants only. All recorded Presentations will be available in the ASN eLearning Center in January 2022.

**Note:** Continuing education credits are not available for Kidney Week On-Demand.

---

64
Sunday, November 6, 8:00 a.m. – 9:00 a.m.

Plenary: Midcareer Awards, State-of-the-Art Lecture .................................................. W415 Valencia
8:00 a.m. In Memoriam
8:05 a.m. Midcareer Awards
8:15 a.m. State-of-the-Art Lecture “Wearable Microfluidic Devices and Implantable Electronic Systems for Kidney Health” – John Rogers

ASN Business Meeting ..................................................................................................... W415 Valencia

Sunday, November 6, 9:30 a.m. – 11:30 a.m.

AKI: Old and New Players ........................................................................................................... W311
Moderators: Pierre Dagher, Kimberly Reidy
9:30 a.m. Protective Neural Circuits in AKI – Mark Okusa
10:00 a.m. Dysregulation of Iron Metabolism in AKI – Subhashini Bolisetty
10:30 a.m. Manipulating Fatty Acid Oxidation to Protect Against AKI – Sunder Sims-Lucas
11:00 a.m. Ferroptosis: New Insights and Links to Metabolism and Redox Biology – Andreas Linkermann

Nephron Progenitor Fate Determination and Maintenance .................................................. W315
Moderators: Cristina Cebrian Ligero, Lori O’Brien
9:30 a.m. Transcriptional Regulation of Nephron Progenitors – Nils Lindstrom
10:00 a.m. Nephron Progenitor Commitment Is a Stochastic Process Influenced by Cell Migration – Alexander Combes
10:30 a.m. Chromatin Interactions with Transcription Factors in Progenitor Maintenance – Pin-Xian Xu Xu
11:00 a.m. Chromatin Accessibility in Progenitors – Dennis Kostka

Contemporary Management of Diabetic Kidney Disease:
Update on Recent Clinical Trials ..................................................................................... W415 Valencia
Moderators: Frank Brosius, Subramaniam Pennathur
9:30 a.m. SGLT2 Inhibitors – Meg Jardine
10:00 a.m. GLP1 Receptor Agonists – Daniël van Raalte
10:30 a.m. Mineralocorticoid Receptor Antagonists – Peter Rossing
11:00 a.m. ASK1 Inhibitors – Glenn Chertow

Ethical Challenges in Nephrology, Including the Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy ................................................................... W304
ASN gratefully acknowledges the Northwest Kidney Centers and its contributors for support of the Christopher R. Blagg Endowed Lectureship in Kidney Diseases and Public Policy.
Moderators: Fahad Saeed, Milda Saunders
9:30 a.m. Dialysis for Patients in the Undocumented Immigrant Community in the United States: The Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy – Lilia Cervantes
10:00 a.m. Ethics of Shared Decision Making in Kidney Diseases – Sara Davison
10:30 a.m. Transplanting Genetically-Modified Pig Kidneys into Humans: A Review of the Ethical Challenges – Peter Reese
11:00 a.m. Ethical Issues in Pediatric Kidney Replacement Therapy – Aaron Wightman
Sunday, November 6, 9:30 a.m. – 11:30 a.m.

Glomerular Diseases and Cancer: Cause or Effect?......................................................................................W414
Support is provided by an educational grant from Travere Therapeutics, Inc.
Moderators: Mark Perazella, Aisha Shaikh
9:30 a.m. Glomerular Diseases in Solid and Hematologic Malignancies: Pathogenesis, Diagnosis, and Management – Pooja Amarapurkar
10:00 a.m. Glomerular Diseases Associated with Cancer Treatment: Mechanism of Disease, Diagnosis, and Management – Naoka Murakami
10:30 a.m. Screening for Cancer in Patients with Newly Diagnosed Glomerular Disease: When Is It Appropriate? – Emmanuelle Plaisier
11:00 a.m. Cancer due to Immunosuppressive Therapy in Glomerular Disease: What Can We Do to Mitigate the Risk? – Kenar Jhaveri

Pending Challenges When Addressing Donor Kidney Function:
How Low Is Low Before and After Donation ..........................................................................................W307
Moderators: Krista Lentine, Aneesha Shetty
9:30 a.m. Should Optimal Pre-Donation GFR Be Based on a Single Flat Cutoff or Based on Age and Gender? – Emilio Poggio
10:00 a.m. Should Donors Be Classified as Having CKD Post-Donation? – Sunita Singh
10:30 a.m. The Hypertensive Kidney Donor: How Far to Push It? – Ann Bugeja
11:00 a.m. Living Donor Prospective on Kidney Donation – Lacye Trevino

Molecular Mechanisms of Hypertension and Cardiovascular Effects......................................................W308
Moderators: Bryan Becker, Mahboob Rahman
9:30 a.m. Elastin-Like Polypeptide: VEGF-B Fusion Protein for Treatment of Preeclampsia – Gene Bidwell
10:00 a.m. Dysregulation of the Circadian Rhythm of BP Is Associated with Adverse Cardiorenal Outcomes – Michelle Gumz
10:30 a.m. CKD Pathogenesis in Hypertension from Human and Animal Genomic Studies – TBD
11:00 a.m. Salt-Induced BP Elevation Is Associated with Impaired Bile Acid Signaling and Monocyte Activation – Jeanne Ishimwe
2022 ACCOMPLISHMENTS

Championing Kidney Care

INTERVENE EARLIER to prevent, diagnose, coordinate care, and educate

- Advanced support across the federal government for early kidney disease testing.
- Prioritized research of new biomarkers and health equity improvements.
- Advocated for Medicare to address the data gap in Medicare Advantage expansion and include people with kidney failure.

TRANSFORM TRANSPLANT and increase access to donor kidneys

- Collaborated with Congress, HRSA, and CMS to increase transparency, accountability, and patient-centered care in the transplantation ecosystem.
- Led successful efforts to remove race factors in eGFR calculations used in the transplant process.
- Advocated for Medicare to provide dental coverage for transplant candidates, recipients, and immunocompromised patients, and supported legislation to allow purchase of dental insurance through federal health care exchanges.

ACCELERATE INNOVATION and expand patient choice

- Secured new federal funding for innovation at KidneyX, research at NIH and NIDDK, and disease surveillance at CDC.
- Advanced reimbursement for increased innovation in TPNIES and TDAPA, while developing payment pathways for an artificial kidney and other innovations.
- Addressed barriers and quality measurement in home dialysis.

ACHIEVE EQUITY and eliminate disparities

- Supported legislation to extend pandemic telehealth expansions.
- Encouraged ASN members to address the impact of climate change on kidney care.
- Outlined recommendations to increase equity and utilization of social determinants of health in kidney care, and provide regular dialysis care for undocumented individuals through Medicaid.

To learn more visit www.asn-online.org/policy
LGBTQ+ Owned and Friendly Local Businesses and Organizations in Orlando

Please join ASN in supporting these local businesses and organizations.

Restaurants

Hamburger Mary’s
110 W Church St
321-319-0600

White Wolf Café & Bar
1829 Orange Ave
407-895-9911

The Hammered Lamb
1235 N Orange Ave
407-704-3200

Café Tu Tu Tango
8625 International Dr
407-248-2222

Island Time
712 E Washington St
407-930-2640

Bites and Bubbles
1618 N Mills Ave
407-270-5085

Estefan Kitchen Orlando
3269 Margaritaville Blvd (Kissimmee)
407-828-0999

Bars and Clubs

Southern Nights
375 S Bumby Ave
407-412-5039

Stonewall Bar Orlando
741 W Church St
407-373-0888

Latitudes
33 W Church St
407-649-4270

Ember
42 W Central Blvd
407-849-5200

Savoy Orlando
1913 N Orange Ave
407-270-4685

Community Organizations

onePULSE Foundation
1912 S Orange Ave, info@onePULSEfoundation.org, 407-775-4611
The Pulse Memorial is a sanctuary of quiet reflection and love dedicated to honoring the senseless lives taken and remembering the horrible attack that occurred on June 12, 2016. ASN is making a $25,000 donation to the foundation to demonstrate our unwavering support of the LGBTQ+ Communities. If you would like to contribute, go to https://secure.qgiv.com/for/asnone/ or text ASN to 505155 or scan this QR code.
Community Organizations (cont.)

The Center Orlando
946 N Mills Ave, info@thecenterorlando.org, 407-228-8272
We look to transform our community by inspiring and connecting people and organization, promoting acceptance and inclusion.

Hope & Help Center of Central Florida
4122 Metric Dr Ste 800 (Winter Park), 407-645-2577
*Founded in 1988 and is the largest HIV/AIDS service and advocacy organization in the Orlando metropolitan area.*

Zebra Coalition
911 N Mills Ave, info@zebrayouth.org, 407-228-1446
Zebra Coalition is a network of organizations which provide services to lesbian, gay, bisexual, transgender, and all youth (LGBTQ+) ages 13–24. The Coalition assists young people facing homelessness, bullying, isolation from their families, and physical, sexual and drug abuse with individualized programs to guide them to recovery and stability.

The Pride Chamber
5003 Old Cheney Hwy, info@thepridechamber.org, 321-800-3946
*We are the LGBT Chamber of Commerce dedicated to the business equality movement in the Greater Orlando area and beyond. The Pride Chamber’s strategic focus is to serve as a resource to small businesses and large corporations and bridge the gap between them. We welcome you to get engaged in our mission to strengthen equality in Greater Orlando’s business community.*

One Orlando Alliance
611 N Mills Ave Box 533005, 407-499-1711
One Orlando Alliance is a vital support network for LGBTQ+ organizations in Central Florida. We lower barriers, provide critical communication, and promote effective, influential, and sustainable opportunities for transforming the culture of the region. We understand transformative change in attitudes and behaviors begins with an unwavering commitment to bettering the welfare of all. We will achieve this by fostering a deep respect for one another and ensuring inclusiveness within our diverse population.

Come Out With Pride
424 E Central Blvd Ste 415 (mail only)
*Come Out With Pride is an all-volunteer nonprofit organization inspired to make an impact in Orlando’s LGBTQ+ community. Celebrated in October, Come Out With Pride welcomes everyone from Central Florida and beyond to come together and #KeepDancingOrlando! We are dedicated to supporting our community through grants and scholarship programs.*

Orlando Youth Alliance
PO Box 536944, info@orlandoyouthalliance.org, 407-244-1222
A 501(c)(3) nonprofit organization founded in 1990. Our mission is to provide a safe space for LGBT youth in Central Florida. We meet on Tuesday evenings at 6:15 p.m. at Reeves United Methodist Church, 110 N Ferncreek Ave.

MBA Orlando LGBT Chamber of Commerce
5003 Old Cheney Hwy, info@thepridechamber.org, 321-800-3946
*Dedicated to the pursuit of equality through economics.*
ASN Innovations in Kidney Education Contest Winners

Congratulations to the winners of the 2022 ASN Innovations in Kidney Education Contest. These winners represent the best of these innovative approaches (relevance, creativity, portability, and feasibility) to teaching about kidney health and diseases.

kidney.wiki
Ryan Town
Stanford University Center for Academic Medicine

Genomics of Kidney Disease Interactive Virtual Modules
Mira T. Keddis, Hana Newman, Harini A. Chakkera, Kara Mangold, Filippo Pinto e Vairo, Mireille El Ters, Marie Hogan, Timothy Curry
Mayo Clinic College of Medicine (Arizona)

Channel Your Enthusiasm: The Burton Rose Book Club
Joel M. Topf, Anna R. Gaddy, Melanie P. Hoenig, Edgar V. Lerma, Sai Sudha, Priti Meena, Roger A. Rodby, Dominique Tomacruz, Juan Carlos Valez, Joshua S. Waitzman, Amy Yau
Oakland University William Beaumont School of Medicine

ASN thanks the contest judges for their review and expertise: Mark G. Parker (chair), Anna Marie Burgner, Katie E. Cardone, Denise K. Link, Rajeev Raghavan, and Hanny Sawaf

Support for the 2022 contest is provided by
Celes Champions: Cele Fogarty Travel Support Program for Patients

On behalf of the 850,000,000 people worldwide with kidney diseases, the Cele Fogarty Travel Support Program for Patients (“Celes Champions”) honors people living with kidney diseases or caring for an individual with kidney diseases by supporting their voice and advocacy.

Cecilia “Celes” Agnes Fogarty was a leading executive in event management and member services for decades, advancing the work of several major organizations in health care, medicine, science, and other areas. She was renowned for her ability to manage the most complex meeting logistics, anticipate challenges, and meet the unexpected crises—large and small—with aplomb and sometimes magic. Her dedication and persistence parallel the courage and diligence to live well with a chronic disease. Throughout her career, Ms. Fogarty mentored countless meeting and event professionals as well as other staff from not-for-profit organizations and the hospitality industry. Prior to her death in 2021, she served as ASN Vice President for Meetings and Member Experience. She and her team were responsible for managing the logistics for ASN Kidney Week, the society’s other national and international events, and related activities.

Despite being diagnosed with kidney disease herself, Ms. Fogarty continued to work towards “A world without kidney diseases,” including the strenuous onsite meeting management, due to the flexibility of peritoneal dialysis, and support of her care team.

Patient advocates who speak out for the people worldwide with kidney diseases.

ASN is committed to including the patient voice throughout the organization and in its activities. To honor Ms. Fogarty, her commitment to mentorship, and her passion for accommodating all people regardless of the challenges they may face, ASN is pleased to announce the inaugural group of “Celes’s Champions” – patient advocates who speak out for the people worldwide with kidney diseases.

• Lubna Akbany
• Jimmie Bates
• Marc Burling
• Nieltej Gedney
• Jackson Goodrich
• Jennifer Meyer
• Janine Reed
• Charles Rice, CPhT
• Wendy Rodgers
SAVE THE DATE

November 2–5, 2023
Philadelphia, PA

www.asn-online.org
Medical Resources and Tools: Partnering With Experts in the Field

GSK is proud to partner with experts in the field to bring you educational resources to support you and your patients.

**Anemia of Chronic Kidney Disease**
[anemiaofckdnetwork.com](http://anemiaofckdnetwork.com)

Explore resources around the clinical burden and unmet needs of anemia of CKD. Learn about:
- The prevalence and burden of untreated anemia of CKD
- The potential impact of anemia of CKD on patients
- Mechanisms of disease in the pathophysiology of anemia of CKD, including the HIF pathway

**Lupus Nephritis**
[sleeducatorsnetwork.com](http://sleeducatorsnetwork.com)

Explore the latest scientific advances and expert opinion in LN
- Learn how you can protect your patients from ESKD through earlier diagnosis and management with therapies that modify the underlying autoimmune disease
- Understand evolving biomarkers and clinical assessments to help inform LN management
- Identify strategies to help remove barriers related to healthcare disparities in LN

**Physician-Patient Discussion:**

Does Patient Care Need to Evolve for Anemia of CKD?

November 5, 2022 | 10:00–10:45AM
Exhibit Hall – West Building

Join Dr. Steven Fishbane and Erich, a patient with anemia of CKD, as they discuss the unmet needs in anemia of CKD. We will also hear the patient perspective on the impact of anemia of CKD on daily life.

**Exhibitor Spotlight**

Explore resources around the clinical burden and unmet needs of anemia of CKD. Learn about:
- The prevalence and burden of untreated anemia of CKD
- The potential impact of anemia of CKD on patients
- Mechanisms of disease in the pathophysiology of anemia of CKD, including the HIF pathway

**Lupus Nephritis**
[sleeducatorsnetwork.com](http://sleeducatorsnetwork.com)

Explore the latest scientific advances and expert opinion in LN
- Learn how you can protect your patients from ESKD through earlier diagnosis and management with therapies that modify the underlying autoimmune disease
- Understand evolving biomarkers and clinical assessments to help inform LN management
- Identify strategies to help remove barriers related to healthcare disparities in LN
Ahead of Kidney Disease Together

Come visit us at BOOTH #1707 and engage with:

- Interactive content for:
  - Anemia of Chronic Kidney Disease (CKD)
  - Lupus Nephritis (LN)
  - Respiratory Syncytial Virus (RSV)
- Hemoglobe - Immersive Augmented Reality Experience
- Anemia of CKD Virtual Reality House
- LN Challenge
- Expert Forums